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ABSTRACT
PURPOSE
Historically, African Americans (AA) have been underrepresented in nutritionrelated behavioral research despite their disproportionate higher risk of cardiovascular
disease (CVD). The Nutritious Eating with Soul (NEW Soul) Study is one of the first of
its kind to recruit an AA only study group to examine CVD prevention via a clinical trial
to examine changes in CVD risk factors across two cohorts who are randomly assigned to
a plant-based, soul food vegan diet or low-fat omnivorous (omni) diet. The purpose of
cost effectiveness analysis (CEA) is to inform clinical and policy decisions and the costs
of interventions that society is willing to pay for. However, few studies have examined
the cost effectiveness of behavioral interventions for AA adults. The purpose of this study
was to evaluate the cost effectiveness of the nutrition and behavior change interventions
of the NEW Soul Study, from a societal perspective, by examining direct costs to deliver
the intervention, and indirect costs reported by participants associated with intervention
adherence.
METHODS
Primary data were collected from AA adults (n=105) between the ages of 18-65
from the Midlands SC region, who enrolled in the NEW Soul Study, across two
cohorts, and were identified as having overweight or obesity (BMI 25–49.9 kg/m2).
Upon completion of baseline assessment of weight, and other laboratory measures,
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participants were randomized to follow a vegan or low-fat omni diet. A cost
effectiveness analysis (CEA) of this randomized control trial is based on one-year
outcomes collected in April 2019 for Cohort 1 and June-July 2020 for Cohort 2. An
incremental cost effectiveness ratio (ICER) over the one-year study period was
calculated based on the intervention (direct) and societal (indirect) costs and weight
loss. Total Costs = Costs to deliver the intervention (ingredients for cooking
demonstrations, meals) + participants’ average cost of weekly groceries + average
weekly costs of dining out. Quality adjusted life year (QALY) was calculated based on
Short Form-12 survey responses that were collected at baseline and one year.
Variations in weight loss between cohorts 1 and 2 before COVID-19 and during
COVID-19 were assessed using a difference-in-difference (DD) study design.
RESULTS
The incremental cost effectiveness ratio (ICER) was $2,888.57 per pound of weight
loss. The results fall within quadrant II of the cost effectiveness plane which indicates that
the vegan diet group, as compared to the omni diet group was more cost effective, as
participants in that diet group experienced greater weight loss in addition to the intervention
costing less. Results from the least squares means estimate from DD models (adjusted for
covariates) reveal that both diet groups experienced some gains in QALY from baseline to
12 months (omni @baseline = 0.7889; omni @ 12 months= 0.804; vegan @baseline
=0.8027; vegan @12 months = 0.808), however there was no statistically significant DD in
QALY between diet groups (Pr > |t| = 0.6485). Pre-COVID, Cohort 1 participants lost an
average of 10.2 pounds at 12 months from baseline. During COVID, Cohort 2 participants
lost an average of 3.7 pounds at 12 months from baseline. The difference-in-differences in
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weight loss pre-COVID and during COVID by diet group revealed a statistically significant
change in weight loss at 12 months compared to baseline between cohorts 1 and 2 for the
vegan diet group (p=0.0408). Pre-COVID (C1), the vegan diet group lost an average of 11
pounds. During COVID (C2), the vegan diet group lost an average of 3.47 pounds.
CONCLUSIONS
The vegan diet intervention produced clinically relevant weight loss at a lower
cost and was therefore cost-effective. Both diet groups experienced similarly minimal
gains in QALYs and the DD in QALYs between the vegan and omni groups was not
statistically significant. DD analysis suggests that the COVID-19 pandemic had an impact
on participants’ ability to achieve greater weight loss in Cohort 2 (compared to Cohort 1),
and significantly inhibited weight loss of participants in the vegan diet group.
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CHAPTER 1
INTRODUCTION
Cardiovascular disease (CVD) accounts for an estimated $448.5 billion in 2008,
from direct (patient care) and indirect (loss/reduced productivity) healthcare
expenditures, an estimated $555 billion in 2016, and a projected estimate of $1.1 trillion
by 2035.1,2 To address the rising costs of health care related to CVD, identifying the root
cause is key3. The primary risk factor for CVD is poor nutrition.4 Poor nutrition is one of
the reasons for racial-ethnic disparities in the prevalence of CVD, primarily due to
disproportionate differences in health status facing African Americans (AA).4,5
Worldwide, CVD is the reason for most deaths for men and women of all races.6
According to 2018 data, 30.3 million American adults were diagnosed with
cardiovascular disease.6 CVD has been the leading cause of death in the United States for
95 years; for 95 years more AA adults disproportionately die from CVD more than
cancer or any other chronic disease condition.2,7–10 AAs in the United State (U.S.) have
higher rates of obesity due to poor nutrition, a risk factor of CVD, compared to Whites
and Hispanics.2 AA foodways, known as the intersection of food and culture, is a unique
contributor to CVD. At the heart of AA foodways is soul food, as it symbolized the
enduring identity of AAs who persevered through slavery by using high amounts of fat
and sodium to prepare soulful dishes from garden produce, food scraps and the poorest
parts of meats.11 This type of cooking has been passed down from generation-to-
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generation and has contributed to the disparity of AAs being diagnosed with CVD at
higher rates.11
Healthful plant-based diets have been shown to help prevent and treat CVD and
promote a healthy body weight. 12,13 Nutrition intervention trials have examined the
impact of weight loss and CVD risk of those following vegan or vegetarian (veg) diets
compared to omnivorous (omni) diets and a recent meta-analysis presented that
participants following a veg diet lost more weight than those assigned to an omni diet.14,15
However, most of these interventions had minimal participation from AAs and have
shown a combination of higher attrition and lower weight loss, that may be due to a
failure to incorporate and address aspects of AA foodways.16 This disparity in
participation results in significant clinical and healthcare spending burdens.17
Hence, there is a critical need to identify and implement culturally relevant
research-based nutrition interventions that are also financially sustainable to combat CVD
within the AA population. Existing literature supports the novel theoretical concept of
applying a cost effectiveness analysis (CEA) to dietary interventions.18–25 Currently, a
cost-effective nutrition intervention for AAs has not been identified, which makes it
difficult to decrease healthcare spending for CVD and make nutrition recommendations
that are culturally acceptable and affordable for those who present with CVD risk factors.
The NEW Soul study, which began in 2017, is one of the first randomized control
trials (RCT) with solely AA participants that incorporates AA foodways through
partnering with local soul food restaurants/chefs to deliver two behavioral nutrition
interventions (vegan and omni low-fat) to AA adults and examines changes in risk factors
for CVD over a two-year period.26 There has been a call to focus on diets versus single
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nutrients in research.27 Both diets of the NEW Soul Study are guided by the Oldways
African Heritage Pyramid, which emphasizes intake of fruits, vegetables, particularly
leafy greens and tubers, and whole grains.28 The NEW Soul Study tests whether a vegan
diet, compared to an omni diet, is effective for CVD prevention and obesity treatment
among an AA population. Prior to this study, no randomized study has examined
differences between these diets among AAs. The design of this intervention is guided by
the Social Cognitive Theory with the goal of increasing participant’s self-efficacy around
sustainable dietary change.29 However, advising future community-based approaches and
population health decision making requires regard of cultural acceptability, costs, and
benefits. A CEA of the NEW Soul Study is innovative because there has not been an
economic analysis, from a societal perspective, of a randomized study that examined the
differences between a vegan and low-fat omni diet among AAs.
STATEMENT OF PURPOSE
The purpose of this cost effectiveness analysis is to: evaluate the NEW Soul
Study for large-scale implementation by assessing the incremental cost per unit of weight
loss in pounds, taking into consideration direct costs to deliver the vegan and omni
nutrition interventions. In our analysis, we will adopt a societal perspective by also
considering the cultural acceptability of dietary recommendations and the costs borne by
participants receiving these interventions. Finally, we will also conduct a cost utility
analysis to determine the cost per quality-adjusted life year (QALY) gained by program
participants.
A cost effectiveness analysis of the NEW Soul Study can help carry out the
mission of the NIH to enhance health and reduce disease by adding new knowledge of a
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culturally relevant nutrition intervention for AAs that will be socially acceptable and may
improve health policy and future health disparities efforts in community and physician
practice settings to reduce the disproportionate burden of CVD.
Costs examined in this study include the costs to deliver and implement the
interventions, such as cooking demonstrations and catering, monetary costs of
participants to follow the assigned diet based on average cost of weekly groceries and
societal costs such as average time spent by participants shopping for food and average
time spent by participants to prepare meals. The major outcome of interest for this study
is weight loss that will be used to calculate an incremental cost effectiveness ratio
(ICER). Furthermore, a change in QALY calculation that will be generated for the two
diet groups based on results of participants’ Short Form-12 (SF- 12) health status survey
at baseline and one year. Additionally, a difference-in-differences (DD) analysis will be
performed to estimate the impact of the COVID-19 pandemic on weight loss of participants
in both diet groups. Based on the results of this study, our long-term goals are to inform
stakeholders and policy makers AA-specific results of this theory-based intervention and
facilitate the process of policy changes related to: physician recommendations for AA
patients who present with risk factors of CVD; and funding and implementation of
interventions in community settings that are affordable and sustainable.
RESEARCH AIMS & METHODLOGY OVERVIEW
Cost effectiveness analysis factors in how interventions improve health, the
resources required, how interventions can reduce health inequities, and affordability and
feasible expectations of the population to adhere to interventions analyzed.30–32
Knowledge of the cost effectiveness of The NEW Soul Study will inform the literature to
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the unknown question of whether a vegan diet or low-fat omni diet is more cost effective,
affordable and feasible within the AA population for weight loss and quality of life.
Additionally, the estimated effect of the COVID-19 pandemic on weight loss of the diet
groups will inform the literature of how global crisis may affect AA participants enrolled
in dietary interventions.
Primary Aim
1a: To test the difference in average weight loss between diet groups.
■ If weight loss is normally distributed, we will use a t-test. If this assumption is
violated, we will use the Wilcoxon test.
Y (dependent variable) = average weight loss
X (independent control variable) = diet group
1b: To conduct a difference-in-difference (DD) regression analysis to explain the
difference in weight loss between diet groups while controlling for age, sex,
education, employment, class attendance, physical activity, and cohort.
! = #0 + b1*t + b2*diet group + b3*diet group*t + b4*age+ b5* sex + b6*education + b7
*employment + b8 *class attendance + b9*physical activity + b10* cohort
H0 for 1b & 1c: Avg Weight lossVegan=Avg Weight lossOmni
HA for 1b & 1c: Avg Weight lossVegan ≠Avg Weight lossOmni
Y (dependent variable) = weight loss at time t

t=0 if baseline; t=1 if 12 months

X (independent variable)= diet group
X (independent control variable) = age, sex, education groups, employment, class
attendance, physical activity, cohort
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1c: To conduct a cost effectiveness analysis with weight loss as an outcome of two
different culturally tailored nutrition interventions at 12 months.
Findings will be presented as an incremental cost effectiveness ratio. A sensitivity
analysis will be conducted to account for degrees of uncertainty.
$%&' =

()*+, %).*!"#$% − ()*+, %).*&'%(
0123ℎ* ,)..!"#$% − 0123ℎ* ,)..&'%(

To calculate weight loss, participants’ weight was taken at baseline and 12 months using
a calibrated digital scale (Healthometer®model 500 KL, McCook, IL). Two
measurements at each time period were taken and averaged. Total weight loss from
baseline to 12 months was averaged for each dietary group. Total costs are calculated
from a societal perspective. This perspective includes aspects of non-health effects that
provide insight into participant’s net benefits or costs associated with the intervention.44
Total Costs = Costs to deliver the intervention (ingredients for cooking demonstrations,
meals) + participants’ average cost of weekly groceries + average weekly costs of dining
out. Cooking demonstration and meal costs to deliver the intervention were collected and
totaled from accounting reports from year one for each diet group and averaged for each
diet group. Literature has determined a connection between costs of food, diet quality,
and obesity and particularly and advocates for the need to identify dietary patterns that
are rich in nutrients and affordable in order to reduce health and nutrition disparities. 27,33
Therefore, participants’ average cost of weekly groceries and dining out was collected at
baseline and 1-year assessments periods. Total costs will be divided by the number of
total participants from each diet group.
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Secondary Aim:
2a: To test the difference in average QALY between diet groups.
■ If average QALY is normally distributed we will use a t-test. If this assumption is
violated, we will use the Wilcoxiam test.
■ Y (dependent variable) = average QALY
■ X (independent variable) = diet group
2b: To conduct a difference-in-difference (DD) regression analysis to explain the
difference in average QALY between diet groups while controlling for age, sex,
education, employment, class attendance, and physical activity.
! = #0 + b1*t + b2*diet group + b3*diet group*t + b4*age+ b5* sex + b6*education + b7
*employment + b8 *class attendance + b9*physical activity + b10* cohort
H0 for 2b & 2c: Avg QALYVegan=Avg QALYOmni
HA for 2b & 2c: Avg QALYVegan ≠Avg QALYOmni
Y (dependent variable) = Avg QALY at time t

t=0 if baseline; t=1 if 12 months

X (independent variable)= diet group
X (independent control variable) = age, sex, education groups, employment, class
attendance, physical activity, cohort
A systematic review of the literature concluded that the Short Form-36 (SF-36)
health status survey was the most widely used measurement tool when assessing the
impact of dietary habits on health related quality of life in a wide variety patients in
clinical settings and persons surveyed is social and research settings.34,35 The SF-36
measures eight domains: physical functions; physical role limitations; bodily pain;
general health perceptions; energy/vitality; social functioning; emotional role limitations;
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and mental health.36(p36) The Short Form-12 (SF-12) health status survey was developed
in 1994 as a sub-set of the SF-36 in order to both reduce respondent burden and to
provide a significant measure of health status; as it measures the same eight domains as
the SF-36.35 The literature suggests that the SF-12 correlates highly with the SF-36 in
patients of all BMI groups and may be more appropriately used in place of the SF-36
when more obesity-related quality of life measures are being used and when respondent
burden is a concern.37 Respondent burden was a concern for our study population since
participants in this study volunteered and completed several other surveys including
dietary food recall surveys at measurement time periods. Therefore, the SF-12 was
selected as the instrument of choice to assess health status for participants enrolled in the
NEW Soul Study at baseline and 12 months.
The Short Form- 6D (SF-6D) is a preference-based instrument for economic
evaluation and was used for this study due to its to classify responses from the SF-12 and
assign health state preference values that were used to calculate QALY via the SF-6D
scoring table.38,39 The decision to utilize this instrument for classification of responses
was based on exploration and conclusions from prior studies that compared the three
most widely used classification systems in the literature: EuroQol five-dimensional (EQ5D); Health Utilities Index (HUI) and the SF-6D.31 Although the EQ-5D is widely used
all over the world in research, clinical settings and for cost utility analysis, it does not
completely capture mental health components for international heart patients who present
with similar heart disease risk factors as participants in this study; nor has it been
included in any large-scale general population surveys in the US.40,41 According to the
literature, the HUI classification instrument is valid and reliable, it is specific to HUI
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questionnaires, so it cannot be applied to classify our participant responses from the SF12.31,42 The SF-6D has been applied widely in the literature as an instrument to estimate
quality of life in lifestyle interventions in the US for diverse populations with
overweight/obesity.31,43,44
In order to classify SF-12 responses, the number of dimensions is reduced from
eight to six by excluding the general health item and combining the role limitation
dimensions (physical and emotional).38 In 2004, four models (algorithms) to calculate
utility were reported in the literature. 38 Models 1 and 2 represent the algorithms to
calculate utility based on classifying responses from the SF-36. Models 3 and 4 represent
the algorithms to calculate utility based on (SF-12). Model 4 was utilized for this study
because it was determined in the literature to be the more consistent and preferred model
because it does not include variables that are not significant at p <0.05.38 Additionally,
levels of each dimension in Model 4 were aggregated if there were any inconsistencies.38
However, this method is limited because it is not current.
More recent literature uses Short Form-6 Dimensions version 2 (SF-6Dv2), an
updated version of the SF-6D that addresses limitations, to classify responses from SF12.45 This classification presents six models of algorithms to calculate utility that were
tested.45 Results indicated Model 3 as the recommended algorithm to estimate QALYs
because of its efficient design using established experimental design procedures and also
due to the model being ordered within dimensions, where increasing severity results in a
decrease in utility.45 However, due to its recent results, this model has not been widely
tested in US populations with AA adults presenting with overweight/obesity. Both
methods were used to calculate utility and the distribution of utility score estimates.
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An average QALY for participants in each diet group will be determined from
SF-12 responses, using both SF-6D and SF-6Dv2 algorithms, by taking 12 month QALY
– baseline QALY of each participant and then calculating an average QALY for
participants in each diet group.31 The objective of this aim is to determine the efficacy of
vegan versus omni diet interventions on QALY. The benefits of assessing QALY as a
measure of health output is that it can simultaneously depict gains from reduced
morbidity and mortality and incorporates it into one measure.31
Tertiary Aim:
3a. To test the difference in average weight loss between cohorts and diet groups.
■ If weight loss is normally distributed we will use a t-test. If this
assumption is violated, we will use the Wilcoxon test.
■ Y (dependent variable) = weight loss from baseline to 12 months
■ X (independent variable) = cohort, diet group
3b. To conduct a difference-in-differences (DD) estimation to assess the likely
impact of COVID-19 on the weight loss in pounds by comparing the changes in
Cohort 2 (affected by COVID-19 at 1 year) to Cohort 1 (not affected by COVID-19
at 1 year).
! = #0 + b1*t + b2*cohort+ b3*cohort*t + b4*age+ b5* sex + b6*education + b7
*employment + b8 *class attendance + b9*physical activity + b10* diet group
H0: Avg Weight lossC1precovid = Avg Weight lossC2duringcovid
H1: Avg Weight lossC1precovid ≠ Avg Weight lossC2duringcovid
Y (dependent variable) = average weight loss
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X (covariates) = age, sex, education groups, employment, class attendance, physical
activity, diet group
Time (Dummy Variable) =>
Intervention (Dummy Variable)=>

1= DURING COVID-19
1= DURING COVID- 19

0= Pre COVID-19
0 = PRE COVID-19

For this study, difference-in-differences estimation is a group of methods that is utilized
to assess the likely impact of the COVID-19 pandemic on weight loss between cohorts
and diet groups.
ORGANIZATION OF THE DISSERTATION
The subsequent chapters provide in-depth details of the literature regarding the
theoretical application of cost effectiveness analysis to nutrition interventions, the
purpose for conducting a CEA of the NEW Soul Study, and the methods utilized to
conduct this research. Additionally, subsequent chapters also provides details of the
literature regarding potential COVID-19 effects on health and weight loss within various
settings (clinical, research and community) and methods used to assess the impact of
COVID-19 on weight loss for participants enrolled in the NEW Soul Study. Chapter 2
provides a critical review of the literature and serves as the foundation and justification
for this research. Chapter 3 provides a comprehensive description of the methodology
used to conduct this research. Chapter 4 details the research conducted to assess the more
cost-effective intervention for African American participants in the NEW Soul Study, and
the findings, limitations, and implications of this study. Chapter 5 details the clinical
assessment protocol established to conduct assessments during the COVID-19 pandemic
and an estimation of the likely impact of COVID-19 on weight loss, and the findings,
limitations and implications of this study.
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CHAPTER 2
LITERATURE REVIEW
This chapter provides a comprehensive review of the literature related to the
dissertation research topic. This chapter details: 1) cardiovascular disease (CVD)
incidence and prevalence in the United States (US); 2) the disproportionate burden
experienced by African Americans (AA); 2) CVD incidence and its effect on healthcare
spending; 3) the relationship between nutrition and CVD health; 4) the ability of primary
care physicians to provide nutrition counseling to reduce AA CVD; 5)
underrepresentation of AAs in nutrition interventions that address CVD; 6) the NEW
Soul Study dietary intervention; 7) theoretical perspectives of applying economic
evaluation to dietary interventions; 8) effects of COVID-19 on health; 9) the purpose of
this research; and 10) the gaps in the literature that will be addressed through this study.
Cardiovascular Disease in the US
Cardiovascular disease has been the leading cause of death in the United States
and causes 1 out of 4 deaths.6,46 In 1979, The U.S. Department of Health and Human
Services launched Healthy People, after the release of Surgeon General Julius
Richmond’s report entitled, Healthy People: The Surgeon General’s Report on Health
Promotion and Disease Prevention.47 10-year goals and objectives related to improving
the overall health and well-being of the American population and preventing death and

injury have been released since its inception in addition to a framework for public health
prevention priorities and action items.48 The first Healthy People 10 year goals were
released in 1990 and included objectives to reduce heart disease, a major cause of
death.48,49
For the past two decades, Healthy People objectives have focused on the
reduction and potential elimination of health disparities by keeping track of mortality
rates, morbidity, health-related risk behaviors, and access to preventative health care by
socioeconomic status and geographic location.49 Healthy People (HP) 2010, 2020 and
2030 specifically stated the intent to improve population cardiovascular health and
quality of life through prevention, detection, and treatment of risk factors for heart attack
and stroke; early identification and treatment of heart attacks and strokes; prevention of
repeat cardiovascular events; and reduction in deaths from cardiovascular disease. 47,48,50
The most common type of heart disease is coronary heart disease. In fact, when
people talk about “heart disease” they often mean coronary heart disease.51 About
630,000 Americans. die from heart diseases each year.51 More than 1 of every 10 (11.7%)
of American adults have been diagnosed with heart disease.7,51 Coronary heart disease
and cardiovascular disease are two medical conditions related to the cardiovascular
system. The term Cardiovascular Disease (CVD) refers to a group of diseases related to
the heart and blood vessels. Coronary heart disease is one of these diseases.51
Progress was made towards some objectives related to CVD, and recessions were
noted in other objectives. However, the commitment to improving cardiovascular to
health and to decrease disparities associated with this disease remains. The goal to
“improve cardiovascular health and quality through prevention, detection, and treatment
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of risk factors for heart attack and stroke; early identification and treatment of heart
attacks and strokes; prevention of repeat cardiovascular events; and reduction in deaths
from cardiovascular disease,” remains a public health priority. 47
Cardiovascular disease represents a wide range of illnesses, including diseases of
the cardiac muscle and the vascular system that supplies the heart, brain and additional
vital organs of the body, such as atrial fibrillation, congestive heart failure, coronary heart
disease, high blood pressure and stroke.52,53 Disease does not occur alone, and
cardiovascular disease is not an exclusion. Cardiovascular health is considerably affected
by the physical, social, and political environment.5,49 The Framingham Heart Study was a
longitudinal cohort study beginning in 1948 that paved the way for much of the
information known today surrounding CVD and cardiovascular (CV) function and the
role that unhealthy diets play in its development.54 The study identified many risk factors
associated with CVD. Risk factors of cardiovascular disease include genetic
predisposition, diabetes, high blood pressure, smoking, a sedentary lifestyle, obesity,
access to affordable and quality health care, and the availability of community support
and resources.24,49,54
CVD incidence increases healthcare spending. According to a 2009 report
published in the New York Times, health care absorbed approximately one dollar in
every six dollars that the nation spent, and this figure surpassed shares spent by any other
nation.20 The Congressional Budget Office projected that this figure will double by
2035.20 Healthcare spending in the United States is the most significant contributor to the
country’s debt and deficits, but our health outcomes are worse that nations who spend
much less on healthcare.21 In the U.S. approximately 1 out of every 3 adults present with
14

some form or CVD risk factors.21 The costs of CVD care contribute greatly to U.S. health
care spending because it is one of the most expensive conditions to treat in US
hospitals.6,55,56 In 2006, the American Heart Association estimated that the cost of CVD
(including CHD, stroke, hypertensive heart disease, and CHF) was $457 billion.57 In
order to put this into perspective, costs for CVD were equal to: “more than half of what
the federal, state, and local governments combined spent on education ($812 billion);
more than two-thirds of what was spent on defense ($622 billion); and more than what
was spent on welfare ($320 billion) and transportation ($229 billion).”58
According to the CDC, nearly 5 million emergency room visits in 2017 were
connected to problems associated with heart and blood vessel problems and more than 72
million Americans made appointments to see their physician related to heart disease.58
The CDC estimated that between 2016-2017 health care costs of heart disease for direct
care ranged from $214 billion to $351 billion with $137 billion going towards care for
lost productivity and $11.5 billion accounting for hospital care from heart attacks.58
Recent projections estimate that by 2035, more than 45 percent of the population will
have cardiovascular disease at a total cost of $1.1 trillion with $748.7 billion going
towards direct medical care costs and $368 billion going towards indirect costs (such as
productivity loss). 52,58 As the nation engages in efforts to reduce healthcare spending,
policy research perspectives published by the American Medical Association show that
lifestyle modifications including nutrition components can contribute to the reduction of
annual health care costs.59
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Obesity/Disproportionate burden of CVD for African Americans/CVD
Determinants
Nutrition components to address CVD aim to reduce obesity prevalence. Obesity
is defined as excess body weight along with an unusually high proportion of body fat, and
)"(#*+ (% -(.&#/$'0

is measured by a body mass index (BMI)- *"(#*+ (% 012$/" '"+"/0 - of ≥30.39,40 Obesity has
been characterized by the American Heart Association as one of the major risk factors for
CVD diseases, such as heart failure (HF), coronary heart disease (CHD), sudden cardiac
death, and atrial fibrillation, and is associated with reduced overall survival.59,60
Obesity has adverse effects on cardiovascular structure and function and studies
show that an increase in obesity prevalence will result in an increased risk of CVD.59
Obesity rates in the United States are alarming and have reached global epidemic
proportions. US obesity prevalence in 2017-2018 was 42.4%.61 For African Americans,
prevalence rates are greater. Between 2017-2018, AA obesity prevalence was 49.6%, as
compared to Hispanics (44.8%) and Whites (44.7%). 2,42 Furthermore, the literature
reveals from population studies, totaling approximately 3.5 million people, that obesity as
measured by BMI has consistently predicted CVD mortality.62–72 Cardiovascular disease
is the leading cause of death in the US, claiming the life of one person every 36 seconds;
although there was a 60% reduction in CVD mortality between 1950-1999; however,
since that time, there has been a consistently widening racial gap in CVD mortality that
has contributed to the black-white life expectancy.7–10,73,74 AA have higher mortality rates
from CVD than any other race (Figure 2.1). 4-7
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Figure 2.1 Coronary Heart Disease Deaths (age adjusted per 100,000 pop) By
Race/Ethnicity75
Southern food culture is the center of southern hospitality, tradition and heritage
and is directly related to CVD prevalence. Southern foodways, (the intersection of food
and culture), contributes to a higher prevalence of obesity.76African Americans define
southern food as soul food to symbolize the enduring identity of African Americans who
persevered through slavery. Stories of enslaved African Americans describe preparing
soulful dishes from rations, garden produce, and the poorest parts of meats that were
hunted on the plantation and this type of cooking has been passed down from generationto-generation.10 Soul food consumed by African Americans contribute to the disparity of
blacks suffering from obesity and being diagnosed with cardiovascular disease at higher
rates than any other racial and ethnic group.9 In 2010, CVD mortality rates per 100,000
were 192.2 for white women, 260.5 for black women, 278.4 for white men, and 369.2 for
black men, whereas the overall death rate from CVD of all races in 2009 was 236.1 per
100,000.19 These alarming statistics are influenced by the social determinants of health:
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genetics, behavior, environmental and physical influences, medical care and social
factors.
Nutrition is key to CVD health. CVD relates to a variety of disorders affecting
the heart and blood vessels, and the likelihood of developing CVD is related to an
unhealthy diet such as: high consumption of sodium, added sugars, processed foods,
animal products and unhealthy fats.77 In 1908, Alexander Ingatowski provided the first
piece of evidence that demonstrated that nutrition contributes to the onset and progression
of CVD proving that high cholesterol intake caused the development of atherosclerosis in
rabbits.78 From that time until the 1990s, nutrition science focused on single-nutrient
based strategies, but it did not appear to be enough to mitigate the onset of CVD.78
Consequently, nutrition science has moved away from examining isolated nutrients and
has advanced towards the importance of food and how overall dietary patterns contributes
to chronic disease or the absence thereof.77
A review of the literature indicates that healthy dietary patterns reveal
commonalities that include high consumption of fiber, whole grains, antioxidants,
vitamins, minerals, polyphenols, monosaturated and polyunsaturated fatty acids and
limited consumption of sodium, refined sugar, saturated and trans fats, and low glycemic
foods.77,78,79 This translates to a high intake of fruits, vegetables, legumes, fish and
seafood, nuts, seeds, whole grains, vegetable oils (mainly, extra virgin olive oil [EVOO]),
and dairy foods together with a low intake of pastries, soft drinks, and red and processed
meat.79,80
A number of epidemiological studies have explored differences in health-related
outcomes based on dietary pattern.81 These patterns have included vegan (contains no
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animal products, favoring grains, legumes, vegetables, and fruit), vegetarian (veg;
contains dairy and eggs), pesco-vegetarian (pesco-veg; contains seafood), semivegetarian (semi-veg; contains all food groups but red meat is limited), and omnivorous
(omni; contains all foods) diets.8
Plant-based diets and low-fat diets are consistently mentioned in the literature in
relation to reduced risk of obesity. Findings from the European Prospective Investigation
into Cancer and Nutrition (EPIC-Oxford) study concluded that people following a vegan
diet gain significantly less weight as they age compared with people following an
omnivorous diet.82 Converting to a diet with higher amounts of plant-based foods also
seems to be protective against weight gain, as does following a pesco-veg diet in
women.82
The first major study to evaluate these dietary patterns within the U.S. was
conducted among the Seventh-day Adventists religious group. Data from the Adventist
Health Study-2 (AHS-2) revealed a strong relationship between meat consumption and
risk of CVD.83 The Adventist Health Study-2 (AHS-2), a large prospective observational
study that has a considerable population of both vegans and AAs, examined diet and
health outcomes among both whites and AAs. Research from the AHS-2 examining
different plant-based eating styles among AAs found that compared with AA omnivores,
AA vegetarians/vegans had significantly lower risk of hypertension, diabetes, and high
total and LDL cholesterol and also concluded that vegans have the lowest body mass
indices (BMIs) and the lowest prevalence of type 2 diabetes.83
Vegan and vegetarian diets have been described extensively in the literature as
beneficial to decrease the risk of cancer, especially in African Americans. Another AHS-
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2 paper found that vegan diets were provided protection against total cancer incidence
(hazard ratio (HR) 0.84, 95% confidence interval (CI) 0.72–0.99) and cancers that are
specific to the female population (HR 0.66, 95% CI 0.47–0.92) as compared with four
other plant-based dietary patterns.84 Plant-based diets may provide even more protection
against chronic disease for AAs than for whites. For example, in an AHS-2 cohort study
examining diabetes risk, diet pattern, and race, researchers found that AA vegans (odds
ratio (OR) 0.381, 95% CI 0.236–0.617), vegetarians (OR 0.618, 95% CI 0.503–0.760),
and semi-vegetarians (OR 0.486, 95% CI 0.312–0.755) had a lower risk of diabetes than
people following an omnivorous diet. 84 This study concluded that in AAs “the dimension
of the protection associated with vegetarian diets was as great as the excess risk
associated with black ethnicity.”24
Vegan and vegetarian diets have also been found to improve overall
cardiovascular health. A review of eight observational studies that evaluated the effect of
plant-based diets on cardiovascular health, revealed that most of the studies revealed
significantly better blood pressure85–89 and fasting glucose levels85–87,89–91 among
vegetarians and vegans. Three studies found significantly lower waist circumferences in
vegetarians and vegans as compared with individuals following other diets,85–87 and two
studies found better triglyceride levels among vegetarians and vegans.86,89 A limitation of
these studies examining dietary pattern and health outcomes is that they were all
observational, which affects their ability to establish causality.
Consuming healthy fats and healthy carbohydrates also play a vital role in
maintaining good cardiovascular health. A systematic review of low-fat diets and the
effect of dietary saturated and trans-fat on heart disease revealed that 8-13% of mortality
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was associated with a higher intake of saturated and transfat.92 Studies also concluded
that CVD was shown to decrease upon replacing saturated fats with polyunsaturated
fats.92,93 Studies have also shown that polyunsaturated fatty acid and monounsaturated
fatty acid in place of saturated fats are effective at decreasing CVD-related events.
Furthermore, eating a diet high in unrefined, high quality carbohydrates in place of
saturated fats has been proven to also lower CHD events such as heart attacks and
strokes.93 Dietary-associated risk has therefore been established as the most important
behavioral factor to target in the prevention of CVD and CVD mortality, and could also
potentially reverse heart disease.77,94 However, translating dietary recommendations into
primary care practice has been difficult.16,95
Primary care physicians are not trained to provide adequate nutrition
counseling to reduce AA CVD incidence and need cost-effective evidence-based
interventions to ensure its sustainability. Public health is a multi-disciplinary field that
aims to 1) prevent disease and death, 2) prolong life, and 3) create environmental
conditions in which people can be healthy through organized interventions at the
institutional, community and societal levels.96,97 Public health signifies the aspiration of
society to improve the overall health and well-being of the population through
dependence on the roles of: government; private sector; the public; and the social
determinants of population health.98 The government’s role in public health is determined
by laws that are authorized and implemented at the federal, state and local levels to
protect the health of the population through agencies that issue regulations and execute
public health programs.97
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Literature has identified that the relationship between the physician and the
patient is very important to help address the public health’s aim to prevent disease and
death.25 National objectives and guidelines present a call to action for physicians to aide
in the reduction of chronic diseases by advising patients on nutrition.15 An objective of
health services research is to help identify how the prevention and treatment of obesity
can be provided to the population at a reasonable cost.18 Primary care settings are visited
most often by obese patients weight- and health-related risk factors of CVD, and in these
settings are also where treatment and nutrition policy recommendations, such as the
United States Department of Agriculture’s (USDA) dietary guidelines, food pyramid and
myplate diagrams are provided.18,99–101 Therefore, primary care physicians have a
distinctive opportunity to intervene and that intervention is vital to improve the health of
the population.
However, a physician’s ability to uphold the public health aim to prevent disease
is dependent upon his or her ability to identify and implement theory and evidence-based
interventions.97,102,103 A survey of adult primary care patients interested in preventing or
reducing risk of CVD disease revealed that when visiting primary care physicians to
address their health needs, they are very concerned about their overall health and wellbeing and desire more suitable nutrition counseling.104 Furthermore, patients feel that
wellness and disease prevention should be priority.102 Even though most physicians
express interest in the association between health and nutrition and desire to uphold
public health aims to prevent disease, they report several barriers to communicating and
making nutrition recommendations to their patients due to a lack of training and
knowledge.5,15,16,24,26,27 Public health researchers have a role by connecting physicians,
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policy makers and community stakeholders to sustainable evidence-based interventions
that address health disparities of CVD.
AAs are historically underrepresented in evidence-based nutrition
interventions that address CVD, and The NEW Soul Study addresses this gap in
literature and provides an opportunity to explore a culturally-appropriate health
economic evaluation of this intervention. Immense progress has been made to address
CVD. Robust National Institutes of Health (NIH)-funded CVD research is our country’s
greatest chance to uncover innovative ways to prevent, treat and ultimately create cures
for cardiovascular disease.52 Greater than 90% of research and training focused on
nutrition is funded by the NIH and the United States Department of Agriculture
(USDA).105 In 2012, the NIH invested $1.7 billion for 4600 nutrition-related research
projects and more than half of all nutrition-related research is funded by the National
Institute of Diabetes and Digestive and Kidney Disease (NIDDK), the National Heart,
Lung and Blood Institute (NHLBI) and the National Cancer Institute (NCI).105 NIHfunded biomedical research has resulted in approximately a 70 percent decline reduction
in the CVD mortality over the last one-hundred years. 52 However, CVD is still the
number one killer, prevalence projections are on the rise, and AAs continue to be
disproportionately affected by CVD.106,107
Literature shows strong evidence relating food to CVD.106 Eating frequency has
increased across: the number of meals consumed each day; the consumption and amount
of snack foods; eating out in restaurants and fast-food; and getting take- out meals.108–114
Additionally, both home and meals purchased elsewhere included higher proportions of
fried and processed foods.112,113,115,116 Due to the persistent prevalence of CVD and the
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connection with food, the American Society for Nutrition (ASN) has been very involved
in advocacy efforts for expanded nutrition research support and established nutritionrelated behavior as a nutrition research priority.105
Research, mostly observational, has indicated that plant-based and low-fat diets
are associated with prevention of chronic disease, healthier body weights, and lowering
CVD risk factors; however, AAs are underrepresented in existing nutrition
interventions.86–91,117–122 A systematic review of weight loss and dietary interventions
involving AAs reveal poor weight loss outcomes and difficulties maintaining weight loss
long-term. 123–126 Research also shows smaller sample sizes and higher attrition rates of
African Americans in nutrition interventions.127–129 Neglecting to address cultural matters
that are applicable to the AA population is one possible reason why it has historically
been difficult to recruit and retain AA research participants for dietary interventions.83,84
The NEW Soul study is significant because it goes beyond studies and is the first
randomized control trial that thoroughly examines the impact of a vegan diet and a lowfat omni diet and CVD outcomes solely in AAs. Both interventions include aspects of the
African American culture, that is often lacking in existing research, such as the
connection between food and religion and modifying traditional soul food recipes to fit
within the study’s dietary guidelines that incorporate the Oldways African Heritage Diet
Food Pyramid.28,130 The NEW Soul diet for the participants randomized to the vegan
group consists of no dairy or animal products, no added oils, 6 servings of grains (mostly
whole grains) daily, 1 – 1 ½ cups of legumes daily, 1 tablespoon of nuts/seeds daily, 2-4
servings of fruit daily, 3-5 servings of vegetables daily and green leafy vegetables daily.26
The NEW Soul diet for participants randomized to the omni group consists of 3-5 ounces
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of lean meats daily, an additional 2 servings of fish each week, ½ - 1 cup of legumes
daily, eggs no more than 2 times/ week, 2-3 servings of low-fat dairy each day, 1
tablespoon of nuts/seeds daily, and healthy oils such as olive/canola, 6 servings of grains
(mostly whole grains) daily, 2-4 servings of fruit daily, 3-5 servings of vegetables daily
and green leafy vegetables daily.26 The goal of the NEW Soul study is to establish the
differences between the two diets on body weight, lipids and blood pressure.
Previous behavioral interventions have shown challenges recruiting AA research
participants due to: a lack of effective recruitment strategies that also do not include a
variety of recruitment methods and historical mistrust of research.131,132 The NEW Soul
Study utilized multiple recruitment methods including, radio advertisements, word of
mouth, TV interviews that results from press releases, online and social media postings,
promotion at local historically black colleges and universities, events that celebrated
black history and culture, and tabling at community outreach at community events.130
Literature reveals that a lack of trust is a significant barrier to positive outcomes
of community-based public health interventions.133 A culturally competent workforce
seeks to build understanding and show respect with others who have different cultural
values, beliefs, and religious practices.105 Establishing a trusting relationship between
researchers and participants through cultural competence is vital since culture influences
individual behavior.134
Recruitment methods utilized in the NEW Soul study included important aspects
to help overcome a long history of mistrust associated with harm done to AA research
participants and a lack of transparency.131 The NEW Soul Study addressed these elements
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by facilitating in-person orientation sessions, conducted by a majority AA staff, that:
engaged participants on a personal level through fun introductions of all persons in
attendance; acknowledged harm that was done to AA research participants through
unethical practices; educated participants about the role of the Institutional Review
Board; detailed operating procedures implemented to protect participants and the privacy
of sensitive information; expressed a commitment to open communication and feedback
on results; engaged interested persons in respectful conversations about AA food and
culture; and provided multiple opportunities for interested persons to ask questions about
the intervention.
Health economic evaluation is critical because resources such as money, time,
and services are limited and costs can be reallocated to prevention strategies that
generate positive health outcomes for vulnerable populations at higher risk for
CVD. Therefore, decision making related to resource management that is guided by
systematic analysis is preferred.31 Systematic analysis helps to identify alternatives that
are significant and reduces the chances of an important alternatives being excluded from
consideration.31 For example, when deciding to introduce a new program that aims to
reduce morbidity, prevention programs may be more efficient than treatment-related
programs.31 Additionally, without quantification, assessments may be misleading.31 An
observational study, based on 12,278 patients who were a part of the Kaiser Permanente
CVD registry, determined that the total mean annual direct medical care costs were $18,
953 for the sample.4 To best manage resources and address health care spending
associated with CVD disparities, the costs of prevention programs is essential to consider.
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With this approach, scientific assessments to explain evidence are specific, and in turn
offers accountability for decisions made on behalf of the population.31
Cost effectiveness analysis is one form of health economic evaluations that
evaluates costs and consequences of alternative interventions. The goal of CEA is to
“maximize societal health benefits” while operating within a constricted budget.32 With
CEA, the ratio of a benefit to cost shows how much of that benefit is achieved per dollar
spent- this can be often described as the “bang for the buck”.135 In comparison, the
intervention providing the largest “bang for the buck” is generally preferred and deemed
as more efficient.135
Cost effectiveness analysis (CEA) is important to: (1) evaluate sustainability
and feasibility of the NEW Soul study for large-scale implementation; (2) provide
AAs with evidence-based dietary recommendations to promote healthy weight loss
and address CVD prevention; and (3) address healthcare spending associated with
CVD by identifying an intervention that will generate a positive return on
investment.31 Based on the burden of CVD on health care spending and the
disproportionate morbidity and mortality of CVD experienced by AAs, a CEA of the
NEW Soul Study addresses a gap in the literature that has not yet been analyzed.
Furthermore, existing literature supports the novel theoretical concept of applying a
cost effectiveness analysis (CEA) to: obesity-related and dietary interventions; chronic
disease-related and dietary interventions.18–25
Cost effectiveness analysis is important to evaluate feasibility of interventions
by considering costs (inputs) and outcomes (consequences) of two different courses of
action implemented via a randomized control trial. 31,136
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CEA of the NEW Soul Study will help to identify the cost per pound of weight
loss the vegan diet group achieves as compared to the omni diet group. A systematic
review of the literature including studies assessing the cost effectiveness of
behavioral interventions concluded that future research should focus on the
sustainability of interventions to evaluate their long-term adherence and benefits due
to decreased adherence related to out-of-pocket participant costs.137,138 Populationbased primary interventions for prevention that include lifestyle modifications can
lower CVD risk factors without increasing healthcare costs, but literature calls for
actions to consider cultural factors, such as acceptability, since they play an important
role in allocating resources towards interventions for scalability purposes.139,140 A
CEA analysis of the NEW Soul Study from a societal perspective includes
components that will assess the financial sustainability of interventions via
affordability of foods/meals, time spent to shop and prepare foods/meals, and cultural
acceptability.
Cost effectiveness analysis shows a long history in the literature to provide
estimates of cost-effective medical care options. In 1981, Ludbrook conducted a CEA
of options for chronic renal failure treatments that were cost effective and produced an
outcome of life years gained.31 Since that time, CEA has expanded to studies that can
be linked to improved patient outcomes and studies related to prevention
interventions. CEA is beneficial to healthcare providers when advising patients on
proper care during medical appointments.31
A key goal of health services research in obesity is to figure out how obesity
prevention and treatment can reach the largest proportion of the population at the least
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possible cost.18 Primary care settings are where people most often seek treatment for
weight-related conditions, so there is an opportunity for early intervention.18,141
Weight loss interventions conducted in primary care settings to treat obesity support
the application of a cost effectiveness analysis. However, results may vary and the
literature advocates assessing long-term cost effectiveness of interventions lasting for
two years or more.18,142 Options include conducting randomized control trials for this
length of time or via modeling. A microsimulation model to determine the Cost
effectiveness of the Study of Technology to Accelerate Research (STAR), a weight
loss intervention for children in a primary care setting, was conducted to estimate
long-term cost effectiveness. The CEA of STAR revealed an expected population
reach of approximately 2 million in ten years, with intervention costs of $119 per child
and $237 per BMI unit reduced.143 The simulation concluded that the STAR
intervention may be more cost-effective than previous interventions because over the
course of ten years, it is expected to prevent 43,000 cases and 226,000 life-years with
obesity at a net cost of $4085 per case and $774 per life-year with obesity averted.143
Assessing long-term cost effectiveness of weight loss interventions can help determine
how obesity prevention and treatment can reach the largest proportion of the
population at the least possible cost.
Cost effectiveness analysis of nutrition treatment for remission of chronic
disease is also supported in the literature. A systematic review of cost effectiveness of
nutrition for the maintenance of remission in Crohn’s disease patients was conducted
and concluded potential nutrition benefits versus no intervention in maintaining
remission and preventing relapse.19 Furthermore, CEA of interventions, that include
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nutrition components, related to treatment options for gastrointestinal disease and
breast cancer.144,145
In some cases, cost effectiveness can be difficult to determine based on where
they fall in the cost effective plane (quadrants I and III). The cost effectiveness of a
12-month, school-based, healthy-eating and active living clustered randomized
contrail trial was evaluated.17 One group received the intervention and completed
three measurement follow ups and the other group completed three measurement
follow-ups but did not receive the intervention.17 The intervention included three
components: teachers provided an extra 30 minutes of daily physical activity; teachers
taught interactive lessons about healthy lifestyles; and school-based cooking
demonstrations were conducted with parents and students. The latter two intervention
components proved to be acceptable and feasible and lower in cost, however the
overall intervention was not cost-effective.17 A systematic review of the cost
effectiveness of non-surgical obesity interventions in men evaluated seven studies and
concluded promising indication of cost effectiveness when interventions targeted
high-risk groups.22 Variation of the delivery of the interventions and imbalances at
baseline methods contributed to high uncertainties, therefore cost effectiveness was
not determined.20,22
In order to assess the highest level of cost effectiveness of dietary
interventions, from a societal perspective, it is preferred that interventions targeting atrisk groups are culturally-tailored or adapted.135 Minority women and men from
diverse cultural and ethnic groups were randomized into groups that received nutrition
and physical activity coaching from members of their community. The studies
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highlighted community health workers from the targeted communities were trained to
provide the culturally-adapted interventions and concluded that the interventions
proved to be cost-effective and quality adjusted life years were also gained.24,146
An estimate of health states in the form of quality-of-life or cost-utility
analysis (CUA) is a variant of CEA and is frequently supported in the literature as a
secondary aim in CEA of dietary interventions.31 The cost effectiveness of a two-year
RCT that assessed weight loss during a dietary intervention with women postpartum
was evaluated.21 Quality of life was assessed using the 36-item Short Form Health
Survey.21 The study concluded that the dietary intervention was cost-effective and
resulted in a two-year weight loss of 8% and cost per gained QALY was 1704-7889
USD. 21 Results of a CEA of a cluster-controlled trail that implemented a system-level
workplace dietary intervention that included nutrition education from an employer
perspective also proved to be cost-effective and improving health-related quality of
life for employees. A CEA of LighterLife Total, a weight reduction program that
worked to address behavioral change and offered group support, was conducted and
compared to no treatment and three other weight reduction programs offered to
participants with obesity. This program was determined to be associated with greater
QALYs and more cost-effective, however it did not include costs from a societal
perspective.25
A cost effectiveness analysis of the NEW Soul Study will provide cost
effective and socially acceptable evidence-based dietary recommendations to promote
healthy weight loss and address CVD prevention amongst AAs. Due to the excessive
expenses associated with the rising costs of healthcare and limited resources,
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economic evaluation via CEA within healthcare has been more popular and was a step
towards controlling costs through rationing healthcare.31,147 Randomized control trials
are most widely used in health evaluation based on its strength in internal validity and
reliability.31 A CEA of this randomized control trial will address healthcare spending
associated with CVD by identifying an intervention for AAs that will generate a
positive return on investment.31
Scientific Premise for Primary & Secondary Aims.
A meta-analysis examining 12 mostly short-term randomized controlled trials
(RCTs) (n=1,151 subjects) was conducted and compared vegan or veg diets to
omni.148 Researchers concluded that participants assigned to veg diets lost
substantially more weight than those assigned to omni diets.148 In sub-analyses,
participants randomized to follow vegan diets lost more weight than participants
assigned to veg diets.148 The results of this study suggest that diet plays an important
role in weight loss, which can improve CVD health. Healthy dietary choices has been
shown to potentially reduce heart attacks by 80% and vegetarian diets may potentially
reduce CVD mortality by 40%.149 Furthermore, plant-based diets are the only known
dietary patterns that have been proven to reverse coronary heart disease.149 However,
identifying interventions to prevent heart disease is not enough. Given the state of
CVD disparities in the AA population and high healthcare spending that is not
equating to better health outcomes, CEA is one tool decision-makers can use to assess
which interventions provide the highest "value for money" and helps them choose the
interventions that maximize the health of the population based on the available
resources. It can also be useful for understanding how much an intervention may cost
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per unit of health gained compared to an alternative intervention.31 The results of a
CEA of The NEW Soul Study, which focuses on heart disease prevention within the
AA population, will enable decision makers to identify which nutrition intervention
(vegan vs. omni), when presented as an incremental ratio, is cost saving when
examining weight loss as an outcome. The results of a CEA examining quality as an
outcome (also known as a cost utility analysis) will enable decision makers to identify
which intervention produces the greatest health benefit. This study provides important
evidence that will contribute to the reduction of CVD disparities by offering new
insights that will inform future nutrition interventions and nutrition recommendations
in clinical practice for AAs.
Scientific Premise for Tertiary Aim.
The world is currently working hard to recover from a global COVID-19
pandemic. Literature revealed that quarantine and isolation has disproportionately
affected individuals in the US with obesity and their ability to manage their weight and
health behaviors despite COVID-19 illness status.148 When asked, patients in health care
settings and public survey respondents consistently reported: spending more time at
home; hardships achieving/maintaining weight loss goals; decreased physical activity;
increased stress eating; decreased dietary restraint; and an increase in anxiety and
depression.148,149,150 A systematic review of the literature that included 36 studies
identified similar trends at the global level.153 However, a critical gap in knowledge about
the impact of COVID-19 on African Americans were largely underrepresented in these
studies. Understanding whether the pandemic had an impact on weight loss of AAs will
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have important implications for future practices to mitigate the risk and spread of illness
while collecting participant measurements such as weight and blood pressure.
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CHAPTER 3
METHODOLOGY

This chapter begins with the study’s purpose, then presents the aims, research
design, how the data were collected, study participant information and limitations of the
study.
Purpose
The purpose of this study is to evaluate the cost effectiveness of the NEW Soul
Study. This was accomplished by assessing the incremental cost per unit of weight
loss, taking into consideration direct costs to deliver the vegan and omni nutrition
interventions. In our analysis, we adopted a societal perspective by also considering the
costs borne by participants receiving these interventions. We will also report on the
change in QALYs gained between the two diet interventions. According to guidelines
for cost effectiveness analysis, a probabilistic sensitivity analysis was conducted in
order to address uncertainties in the model.31 Additionally, variations in weight loss
between cohort 1 (before COVID-19) and cohort 2 (during COVID-19) were assessed
using a DD study design.
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Study Aims
This study has three aims.
Primary aim
1a: To test the difference in average weight loss between diet groups.
■ If weight loss is normally distributed, we will use a t-test. If this assumption is
violated, we will use the Wilcoxon test.
Y (dependent variable) = average weight loss
X (independent control variable) = diet group

1b: To conduct a difference-in-difference (DD) regression analysis to explain the
difference in weight loss between diet groups while controlling for age, sex,
education, employment, class attendance, physical activity, and cohort.
! = #0 + b1*t + b2*diet group + b3*diet group*t + b4*age+ b5* sex + b6*education + b7
*employment + b8 *class attendance + b9*physical activity + b10* cohort
H0 for 1b & 1c: Avg Weight lossVegan=Avg Weight lossOmni
HA for 1b & 1c: Avg Weight lossVegan ≠Avg Weight lossOmni
Y (dependent variable) = weight loss at time t

t=0 if baseline; t=1 if 12 months

X (independent variable)= diet group
X (independent control variable) = age, sex, education groups, employment, class
attendance, physical activity, cohort
1c: To conduct a cost effectiveness analysis with weight loss as an outcome of two
different culturally tailored nutrition interventions at 12 months (Figure 3.1).
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Figure 3.1 Cost Effectiveness Analysis
-

Findings will be presented as an incremental ratio. A sensitivity
analysis will be conducted to account for degrees of uncertainty.
-
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A four-quadrant figure of cost difference plotted against effect
difference will be used to interpret the ICER (Figure 3.2).

-

Figure 3.2 Cost Effectiveness Plane

Secondary Aim:
2a: To test the difference in average QALY between diet groups.
■ If average QALY is normally distributed we will use a t-test. If this assumption is
violated, we will use the Wilcoxon test.
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Y (dependent variable) = average QALY
X (independent variable) = diet group
2b: To conduct a difference-in-difference (DD) regression analysis to explain the
difference in average QALY between diet groups while controlling for age, sex,
education, employment, class attendance, and physical activity.
! = #0 + b1*t + b2*diet group + b3*diet group*t + b4*age+ b5* sex + b6*education + b7
*employment + b8 *class attendance + b9*physical activity + b10* cohort
H0 for 2b & 2c: Avg QALYVegan=Avg QALYOmni
HA for 2b & 2c: Avg QALYVegan ≠Avg QALYOmni
Y (dependent variable) = Avg QALY at time t

t=0 if baseline; t=1 if 12 months

X (independent variable)= diet group
X (independent control variable) = age, sex, education groups, employment, class
attendance, physical activity, cohort
Tertiary Aim:
3a. To test the difference in average weight loss between cohorts.
■ If weight loss is normally distributed we will use a t-test. If this
assumption is violated, we will use the Wilcoxon test.
■ Y (dependent variable) = weight loss from baseline to 12 months
■ X (independent variable) = cohort, diet group
3b. To conduct a difference-in-differences (DD) estimation to assess the likely
impact of COVID-19 on the weight loss in pounds by comparing the changes in
Cohort 2 (affected by COVID-19 at 1 year) to Cohort 1 (not affected by COVID-19
at 1 year).

38

! = #0 + b1*t + b2*cohort+ b3*cohort*t + b4*age+ b5* sex + b6*education + b7
*employment + b8 *class attendance + b9*physical activity + b10* diet group
H0: Avg Weight lossC1precovid = Avg Weight lossC2duringcovid
H1: Avg Weight lossC1precovid ≠ Avg Weight lossC2duringcovid
Y (dependent variable) = average weight loss
X (covariates) = age, sex, education groups, employment, class attendance, physical
activity, diet group
Time (Dummy Variable) =>
Intervention (Dummy Variable)=>

1= DURING COVID-19
1= DURING COVID- 19

0= Pre COVID-19
0 = PRE COVID-19

Target Population
African American adults (18-65 years of age) in the Midlands region of South
Carolina with overweight or obesity (BMI 25-49.9 kg/m2) who enrolled in Cohorts 1 and
2 of the Nutritious Eating With (NEW) Soul Study, a behavioral nutrition intervention,
were chosen for this study. See Table 3.1 for eligibility criteria. All participants
completed an online screening questionnaire and follow-up phone screening to confirm
eligibility criteria listed below.26
Upon completion of the baseline assessment, participants were randomized to one of
two groups: the vegan group or the low-fat omnivorous diet group using a computer
program allocation sequence and stratified by gender and baseline BMI. The cohorts
were separated by one year. Cohort 1 began the study in May 2018 and Cohort 2 began
the study in June 2019. See Table 3.2 for summaries of participant enrollment for both
cohorts. See Table 3.3 for summaries of enrollment and randomization.
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Table 3.1: NEW Soul Eligibility Criteria
Inclusion Criteria

Exclusion Criteria

Self-identify as African American

Following a vegan diet

Be between the ages of 18-65 years

Currently on medication for diabetes

Body Mass Index between 25-49.9kg.m2 Currently pregnant or breastfeeding or
plan to become pregnant in the next 24
months
Live in Columbia, SC/Midlands area
Be able to attend all monitoring and class
visits

Definition of Study Groups
The NEW Soul Study addresses CVD prevention by comparing two diets. Both
diets: are guided by the Oldways African Heritage Food Pyramind; focus on healthier
versions of soul food and traditional African dishes; and highlight meals that are low-fat
and rich in plants.
For the purposes of this study’s primary and secondary aims, the definition of the
vegan group as defined by the NEW Soul study is used to identify participants who
followed a diet that emphasized minimally-processed whole foods from plants, no added
oils, no dairy, and meeting daily protein requirements through nuts, seeds, and beans.26
The definition of the omni group as defined by the NEW Soul study was used to identify
participants who followed an omnivorous diet that emphasized minimally-processed
foods from plants, lean meats, vegetable oils and low-fat dairy products.26
40
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Table 3.2 Demographics of NEW Soul Study Cohort 1 & 2 Participants (N=159)
Before exclusion (N=159)
Cohort 1
Cohort 2
(n=67)
(n=92)
Characteristics
N
% N
%
Gender
Female
59
88.05
67
72.82
Male
8
11.94
25
27.17
Ethnicity
Hispanic or Latino
1
1.5
1
1.09
Not Hispanic or Latino
66
98.5
91
98.91
Race
Black or African American
65
97.01
92
100
African American and other
2
2.99
0
0
race
Age
49.9
Mean (SE)
47.8 (1.4)
48.7 (1.1)
(1.7)
52 (30,
Median (min, max) 50 (25, 65)
50 (25, 65)
65)

After excluding missing values (N=105)*
Cohort 1
Cohort 2
(n=40)
(n=65)
N
%
N
%
36
4

90
10

52
13

80
20

1
39

2.5
97.5

0
65

0
100

40

100

65

0

0

0

0

0

51.1
(1.2)
52
(25,65)

*Note that all participants must self-identify as Black/African American to enroll in the study, but participants may indicate more than
one race.
*Note: After excluding the missing values, there are 105 (66%) participants completed both measures at baseline and month 12.
In Cohort 1, 40 (60%) participants completed both measures; and in Cohort 2, 65 (71%) participants completed both measures.

Table 3.3. NEW Soul Study Participant Enrollment and Randomization
Cohort 1
Cohort 2
Cohorts 1 Complete Data
Total

Total Enrolled

&2

Cohorts 1 & 2

Enrolled @

@ Baseline

Combined

Combined

Baseline

(Baseline & 12
months)

Omni

34

48

82

53

33

44

77

52

Total

67

92

159

105

Participants

(Female=59

(Female= 67

(Female=12

(Female = 88

Male=8)

Male=25)

6 Male=33)

Male =17)

Control
Vegan
Intervention
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Table 3.4 NEW Soul Study- Definition of Study (Dietary) Groups26
VEGAN
Dietary
Recommendations

Whole Grains

OMNI

Emphasized minimallyprocessed whole foods
from plants, no added oils,
no dairy and meeting daily
protein requirements
through nuts, seeds and
beans.

Emphasized minimallyprocessed foods from plants,
lean meats, vegetable oils
and low-fat dairy products

6 servings (mostly whole
grains)

6 servings (mostly whole
grains)

Legumes/Beans

1- 1 ½ cups daily

½ cup – 1 cup daily

Nuts/Seeds

1 tbsp daily

1 tbsp daily

Fruit

2-4 servings daily

2-4 servings daily

Vegetables

Animal Protein

3-5 servings (including
green leafy vegetables)

3-5 servings (including
green leafy vegetables)

•

None

•
•

Dairy

None

3-5 oz. daily of lean
meats (nonprocessed)
Additional 2
servings of fish each
week
No more than 2 eggs
each week/unlimited
egg whites

2-3 servings of low-fat dairy
each day
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Study Design and Methods of Analysis
CEA
A cost effectiveness analysis study design was utilized to compare costs in
relation to weight loss of The NEW Soul Study’s vegan group and omni group. Primary
data collection methods were utilized for this study. Weight loss has been previously used
to determine power in NIH-funded dietary intervention trials. 28 Weight was collected at
baseline and at 12 months. A calibrated digital scale (Healthometer®model 500 KL,
McCook, IL) was used to collect participants’ weight at baseline and 12 months. Two
measurements at each time were taken and averaged. Total costs of the intervention were
calculated from a societal perspective. This perspective includes aspects of non-health
effects that provide insight into participant’s net benefits or costs associated with the
intervention.44 Total Costs = Costs to deliver the intervention (ingredients for cooking
demonstrations, meals) + participants’ average cost of weekly groceries + average
weekly costs of dining out. Cooking demonstration and meal costs to deliver the
intervention were collected and totaled from accounting reports from year one for each
diet group and averaged for each diet group. Literature has determined a connection
between costs of food, diet quality, and obesity and particularly and advocates for the
need to identify dietary patterns that are rich in nutrients and affordable in order to reduce
health and nutrition disparities. 27,33 Therefore, participants’ average cost of weekly
groceries and dining out was collected at baseline and 1-year assessments periods. Total
costs will be divided by the number of total participants from each diet group. The
difference in costs between the vegan and omni diet interventions will then be divided by
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difference in weight loss between the vegan and the omni diet interventions resulting in
the incremental cost effectiveness ratio (ICER).
ICER Interpretation
A cost effectiveness plane is used to interpret the ICER.31 The horizontal axis
characterizes the difference in effect between the vegan diet intervention and the
alternative (omni diet intervention).31 The vertical axis characterizes the difference in
costs; if the ICER falls in quadrants II or IV of the cost effectiveness plane, then the
choice between whether the vegan diet intervention or the omni diet intervention is more
cost effective is without question.31 The ICER falls in Quadrant II and is interpretated as
the vegan diet group being more effective and less costly than the omni diet
intervention.31 That would mean that the diet group intervention of interest dominates the
alternative. If the ICER falls in quadrant IV, then the opposite applies- the alternative
dominates the diet group intervention of interest. If the ICER falls within quadrants I or
III, then the choice of the intervention is based on the maximum cost effectiveness ratio
that the decision maker is willing to accept.31
Sensitivity Analysis
Probabilistic sensitivity analysis is required in guidelines for cost effectiveness
analysis to address uncertainties in the model. 28 Therefore, a Monte Carlo probabilistic
sensitivity analysis will be conducted to assess the robustness of the findings by
examining what can potentially happen and the likelihood of each outcome in order to
ensure that the results are acceptable for decisions related to scaling up this intervention
in clinical and community settings.38 Additionally, in relation to a clinical study, it is
common that some participants have much higher costs that have more of an effect on the
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mean costs, and skew the distribution.31 Since the reported ICER is a ratio, it is not
appropriate to use standard statistical techniques to assemble confidence intervals.31
A detailed literature review was conducted by Mihaylova and colleagues to
describe alternative methods that can be used and three in particular were recommended:
ordinary least squares (OLS) regression; OLS with transformation to the log scale and
bootstrapping.154 The OLS method is based on normal distribution but estimates of mean
weight loss can be sensitive to extreme values for individual level participant costs. The
OLS with transformation method can be used when the probabilities are larger than those
of the exponential distribution.31 Since our study consisted solely of individual patientlevel data, the bootstrapping method is the more appropriate non-parametric alternative
for this study to describe the distribution of possible mean values of weight loss.31 This
method uses resampling from the data with replacements to produce a practical estimate
of the sampling distribution of mean costs.31 10,000 bootstrap samples were created to
show the uncertainty and acceptability curve. By repeatedly drawing a random sample
with replacement, a scatter plot of 10,000 bootstrapped incremental cost effectiveness
ratios, this produced estimates of the likelihood that the vegan diet intervention was cost
effective compared to the omni diet intervention based on the $50,000 - $150,000 US
willingness to pay threshold.
Acceptability Curve
The acceptability probability was estimated as the proportion of accepted ICER
out of the 10,000 ICER samples. The willingness to pay is based on 1.84 GDP per capita
($50,000) to 2.76 GDP per capita ($150,000), which is reflective of literature used to
assess willingness to pay in the United States.136 By increasing the willingness to pay,
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acceptance probability values can be estimated. An acceptability curve can then be
plotted with the x axis representing the willingness to pay per 1 pound of weight loss and
the y axis representing the estimated acceptance probability.
Quality of Life Measurements
Quality of life (QOL) was measured using the SF-12, which includes 12 questions
(Q). These 12 questions can be grouped in to 8 domains of general health (Q 1), physical
functioning (Q 2-3), limitations in physical role functioning of physical health (Q 4-5),
limitations in emotional problems (Q 6-7), pain (Q 8), mental health (Q 9-10), vitality (Q
11) and social functioning (Q 12).38
There are two steps to calculate QALY: 1) SF-12 must be converted into SF-6D
health state classification system; and 2) utility scores must be estimated based on SF-6D
classification. A search of the literature revealed two studies (2004, 2020) using two
different methods to calculate utility.38,45 Both methods will be applied to calculate
QALY and the distribution of the results from the two methods will be compared.
In order to classify SF-12 responses, the number of dimensions is reduced from
eight to six by excluding the general health item and combining the role limitation
dimensions (physical and emotional).38 By using SF-6D (2004), Q2 was selected for
physical functioning domain; Q5 and Q6 were combined into 4 levels for role functioning
(You have no problems with your work or other regular daily activities as a result of your
physical health or any emotional problems; You are limited in the kind of work or other
activities as a as a result of your physical health; You are limited in the kind of work or
other activities as a as a result of emotional problems; You are limited in the kind of work
or other activities as a as a result of your physical health and accomplish less than you
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would like as a result of emotional problems ); Q8 was selected for pain, Q10 was
selected for mental health, Q11 was selected for virality and Q12 was selected for social
functioning.
In the 2020 paper, Short Form-6 Dimensions version 2 (SF-6Dv2), an updated
version of the SF-6D that addresses limitations, was developed to classify responses from
SF-12.45 Questions selected using the SF-6Dv2 (2020) paper were the same as SF-6D
(2004), except that Q4 and Q6 was combined into 5 levels for role functioning
(Accomplish less than you would like none of the time; Accomplish less than you would
like a little of the time; Accomplish less than you would like some of the time;
Accomplish less than you would like most of the time; and Accomplish less than you
would like all of the time). Details are presented in Table 3.5.
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Table 3.5- SF-12 Domain and Question Classification for SF-6D and SF-6Dv2

SF-12 Domains/items

Selected for
SF-6Dv2
(2020
paper)

Summary of contents

Response levels

In general, would you say that
your health is

1 - Excellent; 2 - Very good; 3 - Good;
4 - Fair; 5 - Poor
×

Selected
for SF6D (2004
paper)

General Health
Q1

×

Physical functioning
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Moderate activities, such as
moving a table, pushing a
vacuum cleaner, bowling, or
playing golf
Climbing several flights of
stairs

1 - Yes, limited a lot; 2 - Yes, limited
a little; 3 - No, not limited at all
1 - Yes, limited a lot; 2 - Yes, limited
a little; 3 - No, not limited at all

Q4

During the past 4 weeks, how
much of the time have you
accomplished less than you
would like as a result of your
physical health

Q5

During the past 4 weeks, how
much of the time were you
limited in the kind of work or
other regular daily activities

Q2
Q3
Role functioning
(physical health)

√
(3 out of 5
levels
match)

√

×

×

1 - All of the time; 2 - Most of the
time; 3 - Some of the time; 4 - A little
of the time; 5 - None of the time

√

×

1 - All of the time; 2 - Most of
the time; 3 - Some of the time; 4
- A little of the time; 5 - None of
the time

×

√

you do as a result of your
physical health
Role functioning
(emotional problems)

Q6
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Q7

During the past 4 weeks, how
much of the time have you
accomplished less than you
would like as a results of any
emotional problems, such as
feeling depressed or anxious
During the past 4 weeks, how
much of the time did you do
work or other regular daily
activities less carefully than
usual as a result of any
emotional problems, such as
feeling depressed or anxious

1 - All of the time; 2 - Most of the
time; 3 - Some of the time; 4 - A little
of the time; 5 - None of the time

√

√

1 - All of the time; 2 - Most of the
time; 3 - Some of the time; 4 - A little
of the time; 5 - None of the time

×

×

During the past 4 weeks, how
much did pain interfere with
your normal work, including
both work outside the home
and housework

1 - Not at all; 2 - A little bit; 3 –
Moderately; 4 - Quite a bit; 5 Extremely

√
(5 out of 6
levels
match)

√

How much of the time during
the past 4 weeks have you felt
calm and peaceful

1 - All of the time; 2 - Most of the
time; 3 - Some of the time; 4 - A little
of the time; 5 - None of the time

×

×

Pain

Q8
Mental health
Q9

Q10

How much of the time during
the past 4 weeks have you felt
downhearted and depressed

1 - All of the time; 2 - Most of the
time; 3 - Some of the time; 4 - A little
of the time; 5 - None of the time

√

√

How much of the time during
the past 4 weeks did you have
a lot of energy

1 - All of the time; 2 - Most of the
time; 3 - Some of the time; 4 - A little
of the time; 5 - None of the time

√

√

During the past 4 weeks, how
much of the time has your
physical health or emotional
problems interfered with your
social activities like visiting
with friends or relatives

1 - All of the time; 2 - Most of the
time; 3 - Some of the time; 4 - A little
of the time; 5 - None of the time

√

√

Vitality
Q11
Social functioning
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Q12

For step two, the utility score was calculated based on SF-6D and SF-6Dv2. In the
2004 paper using SF-6D, four models (algorithms) to calculate utility were reported in
the literature. 38 Models 1 and 2 represent the algorithms to calculate utility based on
classifying responses from the SF-36. Models 3 and 4 represent the algorithms to
calculate utility based on (SF-12). Model 4 was utilized for this study because it was
determined in the literature to be the more consistent and preferred model because it does
not include variables that are not significant at p <0.05.38 Additionally, levels of each
dimension in Model 4 were aggregated if there were any inconsistencies.38 The SF-6Dv2
classification presents six models of algorithms to calculate utility that were tested.45
Results indicated Model 3 as the recommended algorithm to estimate QALYs because of
its efficient design using established experimental design procedures and also due to the
model being ordered within dimensions, where increasing severity results in a decrease in
utility.45 However, due to its recent results, this model has not been widely tested in US
populations with AA adults presenting with overweight/obesity. Both methods were used
to calculate utility and the distribution of utility score estimates.
The algorithms for each are listed in Table 3.6. Our study participants completed
the first version of the SF-12 and the levels for physical functioning and pain do not
align. Therefore, our modified coefficients to estimate the utility score for physical
function are: 0 (Limited in vigorous activities not at all); -0.034 (Limited in moderate
activities a little); and -0.092 (Limited in moderate activities a lot). For pain: 0 (No pain);
-0.076 (Very mild pain); -0.139 (Moderate pain); -0.46 (Severe pain); and -0.62 (Very
severe pain). The range of utility scores by the SF-6Dv2 algorithm may exceed the 0-1
range. To account for this, we will cap the QALY at zero for any values below zero.
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Table 3.6- SF-6D & SF-6Dv2 Utility Algorithms
SF-6Dv2
Classification
System (2020)
Physical
functioning (5
levels)
Limited in
vigorous
activities not at
all
Limited in
vigorous
activities a little
Limited in
moderate
activities a little
Limited in
moderate
activities a lot
Limited in
bathing and
dressing a lot
Role functioning
(5 levels)

Match
with
SF-12

SF-6D
Classification
System (2004)
Physical
Model
functioning (3
Coefficients
levels)

Yes

0

No

-0.019

Yes

-0.034

Yes

-0.092

No

-0.186

Accomplish less
than you would
like none of the
time

Yes

0

Accomplish less
than you would
like a little of the
time

Yes

-0.039

Accomplish less
than you would
like some of the
time

Yes

-0.055

Your health does
not limit you in
moderate activities

Your health limits
you a little in
moderate activities
Your health limits
you a lot in
moderate activities

Match
Model
with
Coefficients
SF-12
Yes

0

Yes

0

Yes

-0.045

Role functioning
(4 levels)
You have no
problems with your
work or other
regular daily
activities as a result Yes
of your physical
health or any
emotional
problems
You are limited in
the kind of work or
other activities as a Yes
as a result of your
physical health
You are limited in
the kind of work or
Yes
other activities as a
as a result of
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0

-0.063

-0.063

Accomplish less
than you would
like most of the
time

Accomplish less
than you would
like all of the
time
Social
functioning (5
levels)

Yes

-0.099

Yes

-0.102

emotional
problems
You are limited in
the kind of work or
other activities as a
as a result of your
physical health and
accomplish less
than you would
like as a result of
emotional
problems

-0.063

Yes

0

Yes

-0.063

Yes

-0.066

Yes

-0.081

Yes

-0.093

Yes

0

Social functioning
(5 levels)

Social activities
are limited none
of the time

Yes

0

Social activities
are limited a little
of the time

Yes

-0.008

Social activities
are limited some
of the time

Yes

-0.029

Social activities
are limited most
of the time

Yes

-0.103

Social activities
are limited all of
the time

Yes

-0.137

Yes

0

Your health limits
your social
activities none of
the time
Your health limits
your social
activities a little of
the time
Your health limits
your social
activities some of
the time
Your health limits
your social
activities most of
the time
Your health limits
your social
activities all of the
time
Pain (5 levels)
You have pain that
does not interfere
with your normal
work (both outside

Pain (6 levels)
No pain

Yes
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Very mild pain

Yes

-0.076

Mild pain

No

-0.097

Moderate pain

Yes

-0.139

Severe pain

Yes

-0.46

Very severe pain

Yes

-0.62

the home and
housework) at all
You have pain that
interferes outside
with your normal
work (both outside
the home and
housework) a little
bit
You have pain that
interferes outside
with your normal
work (both outside
the home and
housework)
moderately
You have pain that
interferes outside
with your normal
work (both outside
the home and
housework) quite a
bit
You have pain that
interferes outside
with your normal
work (both outside
the home and
housework)
extremely
Mental health (5
levels)
You feel
downhearted and
low none of the
time
You feel
downhearted and
low a little of the
time

Mental health (5
levels)
Depressed or very
nervous none of
Yes
the time

0

Depressed or very
nervous a little of Yes
the time

-0.026

Depressed or very
nervous some of
Yes
the time

-0.086

You feel
downhearted and
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Yes

0

Yes

-0.042

Yes

-0.077

Yes

-0.137

Yes

0

Yes

-0.059

Yes

-0.059

Depressed or very
nervous most of
Yes
the time
Depressed or very
nervous all of the Yes
time
Vitality (5 levels)

-0.236

-0.324

Worn out none of
the time

Yes

0

Worn out a little
of the time

Yes

-0.015

Worn out some of
Yes
the time

-0.015

Worn out most of
the time

Yes

-0.08

Worn out all of
the time

Yes

-0.121

Worst

low some of the
time
You feel
downhearted and
low most of the
time
You feel
downhearted and
low all of the time
Vitality (5 levels)
You have a lot of
energy all of the
time
You have a lot of
energy most of the
time
You have a lot of
energy some of the
time
You have a lot of
energy a little of
the time
You have a lot of
energy none of the
time
Worst

-0.084
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Yes

-0.113

Yes

-0.134

Yes

0

Yes

-0.078

Yes

-0.078

Yes

-0.078

Yes

-0.106
-0.077

Change in QALY
QALY change from baseline to 12 months was calculated based on the change in
utility scores multiplied by the duration of the study (1 year). Participants in the NEW
Soul Study were asked to recall their health conditions during the past 4 weeks at
baseline and 12 months. We believe the estimated utility score during the past 4 weeks
for each measurement period appropriately reflects the health condition of our study
participants.
Ethical Procedures Approval
The data used in this study was collected by NEW Soul Study Staff. Data is deidentified. Institutional Review Board approval was granted to collect this data.
Limitations
This CEA involves a comparison of two dietary “courses of action” of the NEW
Soul study that aim to reduce obesity, a major CVD risk factor. The difference in costs of
the vegan and omni diets s are compared with the difference in outcomes. However, there
are some questions that a CEA of the NEW Soul Study cannot answer. This study is
subject to limitations because it is limited in scope to the NEW Soul Study specifically
and does not take into account all potential diet patterns to address CVD prevention. This
study does not include all outcomes associated with the intervention, such as lipid panel
results to assess cholesterol levels and blood pressure. Selection bias can also occur since
all participants volunteered for this study. Participants may share social characteristics
that are different from others who did not volunteer to participate. Life changing events,
such as, but not limited to changes in: income, household size and marital status.
However, we do not expect that these changes will be different between groups.
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Threats to the validity of the study include: attrition; data underreporting or
overreporting; and measurement error. Attrition is a threat to the validity of this study,
because not all participants participated in the 12-month assessment where weight was
collected. Data underreporting or overreporting may also have been present, as
participants may have underreported or overreported the average amount of money they
spent on groceries and dining out, and/or their time spent shopping and preparing food. If
this data was underreported or overreported, it would not reflect the true costs associated
with the diet group that is used to calculate the ICER. Measurement error may have also
resulted due to participants answering questions retrospectively and inaccurately recalling
information. Additionally, measurement error could have resulted during the collection of
weight and/or during the entry of that data.
Significant measures were taken by the NEW Soul Staff to assure the reliability
and validity of the data. These measures included: frequent communication with
participants to maximize participation in assessments to collect weight; helpful text
within the surveys to ensure that participants understood survey questions that were
designed with an upper elementary reading level; and collecting two weight
measurements that were recorded and triple checked upon entering the data.
Despite these challenges, cost effectiveness analysis clarifies and quantifies the
potential impact of the NEW Soul Study and results provide useful information to
determine feasible and culturally acceptable diet recommendations for CVD prevention.
Because this analysis was conducted from a societal perspective, it provides the best
indication of overall cost effectiveness of the interventions and is very useful for
decisions related to the allocation of resources.30,155
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CHAPTER 4
MANUSCRIPT ONE
A COST EFFECTIVENESS ANALYSIS OF THE NUTRITIOUS EATING WITH
SOUL STUDY

1

Wilson, M.J., Crouch, E., Chen, B., Turner-McGrievy, B., Hung, P. ……To be submitted.
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Abstract
Background
The present study is an economic evaluation of the NEW Soul Study (previously
described in the literature)-comparing a vegan diet group to an omni diet group- for the
prevention of cardiovascular disease (CVD) in an African American (AA) study
population.26
Methods
Cost Effectiveness Analysis
Total costs were calculated from a societal perspective. Total Costs = Costs to deliver the
intervention (ingredients for cooking demonstrations, meals) + participants’ average cost
of weekly groceries + average weekly costs of dining out. Weight loss and quality
adjusted life year outcomes were evaluated at baseline and 12 months for each dietary
group. Cost effectiveness analysis findings was reported as an incremental ratio (ICER)
based on the total costs of the vegan diet minus the total cost of the omni diet, divided by
the average weight loss of the vegan diet group minus the average weight loss of the
omni group. A four-quadrant plane of cost difference plotted against weight loss
difference was used to interpret the ICER. Probabilistic sensitivity analysis was used to
test model robustness.
QALY
Quality of life was measured using the Short-Form 12 (SF-12) Health Status Survey. The
SF-12 consists of 12 questions grouped into eight dimensions: general health, physical
functioning, role functioning (physical health), role functioning (emotional health), pain,
mental health, and social functioning. Each dimension was scored to calculate utility for
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using the Short Form- 6 Dimensions (SF-6D) and Short Form-6 Dimensions version 2
(SF-6Dv2). The SF- 6D (6 domains) preference-based instrument was used to classify
responses from the SF-12 (8 domains). Health state preference values (utilities) were
calculated via Model 4 of the scoring table based on Brazier & Roberts distribution
matching and methods with 0 indicating worst health/death and 1 indicating perfect
health.38 Classifying the 8 domains of SF-12 to SF-6 domains resulted in the removal of
the general health question and combining role limitations questions to assess the
physical and emotional aspects.38 The SF-6Dv2 (6 domains), an updated classification
instrument that addresses limitations of the SF-6D (resulting in a more narrow range of
utilities), was also used to classify responses from the SF-12.45 Utilities were calculated
via Model 3 due to its efficient design using established experimental design procedures
and the model being ordered within dimensions, where increasing severity results in a
decrease in utility.45 The distribution of utility score estimates from the SF-6D and the
SF-6Dv2 algorithms were calculated and results were compared via a density plot.
Quality adjusted life years (QALY) gained between baseline and 12 months were
calculated for each classification method for each diet group using the formula: QALYs
gained = (12 month utility – baseline utility) *1 (duration of the study). This formula
focuses on the change in utility between baseline and 12 months and assumes that these
values accurately reflect the health condition of participants over the course of the
intervention.
Findings
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The incremental cost effectiveness ratio (ICER) was $2,888.57 per pound of weight loss.
The results fall within quadrant II of the cost effectiveness plane which indicates that the
vegan diet group, as compared to the omni diet group, is dominate and by costing less and
achieving greater weight loss for participants enrolled in the NEW Soul Study. Results on
QALY based on SF-6D classification indicate that the difference in 12 month and baseline
QALY for the omni diet group is 0.01508 and that the difference in 12 month and baseline
QALY for the vegan diet group is 0.005327. The difference-in-differences (DD) in QALY
between the vegan and omni diet groups is -.00975 and there is no statistically significant
difference in QALY between the diet groups.
Conclusions
For AAs presenting with CVD risk factors, results of CEA indicate that the choice
between the diet interventions is clear: the vegan diet intervention is more cost effective
and the ideal choice for AAs desiring to lose weight. QALY calculations reveals no
significant difference between the diet groups in terms of QALY gained from baseline to
12 months.
Keywords: economic analysis, cost effectiveness, cardiovascular disease, dietary
intervention
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Introduction
Worldwide, cardiovascular disease is the reason for most deaths for men and
women of all races.6 In 2018, 30.3 million American adults were diagnosed with
cardiovascular disease.6 Cardiovascular disease (CVD) accounts for an estimated $448.5
billion in 2008, from direct (patient care) and indirect (loss/reduced productivity)
healthcare expenditures, an estimated $555 billion in 2016, and a projected estimate of
$1.1 trillion by 2035.1,2 In the United States, CVD has been the leading cause of death for
almost 100 years; and for almost 100 years more African American (AA) adults
disproportionately die from CVD more than cancer or any other chronic disease
condition.2,7–10 AAs in the United State (U.S.) have higher rates of obesity due to poor
nutrition, a risk factor of CVD, compared to Whites and Hispanics.2 African American
foodways, known as the intersection of food and culture, is a unique contributor to CVD.
At the heart of AA foodways is soul food, as it symbolized the enduring identity of AAs
who persevered through slavery by using high amounts of fat and sodium to prepare
soulful dishes from garden produce, food scraps and the poorest parts of meats.11 This
type of cooking has been passed down from generation-to-generation and has contributed
to the disparity of AAs being diagnosed with CVD at higher rates.11
To address the rising costs of health care related to CVD, there is a critical need to
identify and implement culturally relevant research-based nutrition interventions to
combat CVD within the AA population that are sustainable and a good investment of
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resources. Existing literature supports the novel theoretical concept of applying a cost
effectiveness analysis (CEA) to dietary interventions.18–25
The NEW Soul study, as previously described in the literature, is one of the first
randomized control trials (RCT) with solely AA participants that incorporates AA
foodways through partnering with local soul food restaurants/chefs to deliver two
behavioral nutrition interventions (veffgan and omnivorous low-fat) to AA adults and
examines changes in risk factors for CVD over a two-year period.26 However, advising
future community-based approaches and population health decision making requires
further investigations in regard of cultural acceptability, costs, and benefits. To our
knowledge, a cost-effective nutrition intervention for AAs has not been identified, which
makes it difficult to decrease healthcare spending for CVD and make nutrition
recommendations that are culturally acceptable and affordable for those who present with
CVD risk factors.
Therefore, this study is aimed to evaluate the NEW Soul Study for large-scale
implementation by assessing the incremental cost per unit of weight loss in pounds,
taking into consideration direct costs to deliver the vegan and omni nutrition
interventions. In our analysis, we adopted a societal perspective by also considering the
cultural acceptability of dietary recommendations and the costs borne by participants
receiving these interventions. Additionally, we also calculated health state utilities to
determine the cost per quality-adjusted life year (QALY) gained by program participants
from baseline to 12 months and to determine the difference-in-differences of QALY for
the diet groups.
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Methodology
Population studied
African American adults (18-65 years of age) in the Midlands region of South
Carolina with overweight or obesity (BMI 25-49.9 kg/m2) who enrolled in Cohorts 1 and
2 of the Nutritious Eating With (NEW) Soul Study, a behavioral nutrition intervention,
were chosen for this study. All participants completed an online screening questionnaire
and follow-up phone screening to confirm eligibility criteria listed below (Table 4.1).26
Table 4.1: NEW Soul Eligibility Criteria
Inclusion Criteria

Exclusion Criteria

Self-identify as African American

Following a vegan diet

Be between the ages of 18-65 years

Currently on medication for diabetes

Body Mass Index between 25-49.9kg.m2

Currently pregnant or breastfeeding or
plan to become pregnant in the next 24
months

Live in Columbia, SC/Midlands area
Be able to attend all monitoring and class
visits

Upon completion of the baseline assessment, participants were randomized to one of
two groups: the vegan group or the low-fat omnivorous diet group using a computer
program allocation sequence and stratified by gender and baseline BMI. The cohorts
were separated by one year. Cohort 1 began the study in May 2018 and Cohort 2 began
the study in June 2019. See Table 4.2 for summaries of participant enrollment for both
cohorts. See Table 4.3 for summaries of enrollment and randomization.
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Table 4.2. Demographics of NEW Soul Study Cohort 1 & 2 Participants (N=159)
Before exclusion (N=159)
Cohort 1
Cohort 2
(n=67)
(n=92)
Characteristics
N
% N
%
Gender
Female
59
88.05
67
72.82
Male
8
11.94
25
27.17
Ethnicity
Hispanic or Latino
1
1.5
1
1.09
Not Hispanic or Latino
66
98.5
91
98.91
Race
Black or African American
65
97.01
92
100
African American and other
2
2.99
0
0
race
Age
49.9
Mean (SE)
47.8 (1.4)
48.7 (1.1)
(1.7)
52 (30,
Median (min, max) 50 (25, 65)
50 (25, 65)
65)

After excluding missing values (N=105)*
Cohort 1
Cohort 2
(n=40)
(n=65)
N
%
N
%
36
4

90
10

52
13

80
20

1
39

2.5
97.5

0
65

0
100

40

100

65

0

0

0

0

0

51.1
(1.2)
52
(25,65)

**All participants must self-identify as Black/African American to enroll in the study, but participants may indicate more than one
race.
*** After excluding the missing values, there are 105 (66%) participants completed both measures at baseline and month 12.
In Cohort 1, 40 (60%) participants completed both measures; and in Cohort 2, 65 (71%) participants completed both measures

Table 4.3 NEW Soul Study Participant Enrollment and Randomization
Cohort 1
Cohort 2
Cohorts 1 & 2
Total Enrolled Total Enrolled
Combined
@ Baseline
@ Baseline

Omni Control
Vegan
Intervention
Total
Participants

34
33

48
44

82
77

67
(Female=59
Male=8)

92
(Female= 67
Male=25)

159
(Female=126
Male=33)

Complete
Data
Cohorts 1
&2
Combined
(Baseline
& 12
months)
53
52
105
(Female =
88 Male
=17)

Definition of Study Groups
The NEW Soul Study addresses CVD prevention by comparing two diets. Both
diets are guided by the Oldways African Heritage Food Pyramid, focusing on healthier
versions of soul food and traditional African dishes; and highlighting meals that are lowfat and rich in plants.
For the purposes of this study, the definition of the vegan group as defined by the
NEW Soul study is used to identify participants who followed a diet that emphasized
minimally-processed whole foods from plants, no added oils, no dairy, and meeting daily
protein requirements through nuts, seeds, and beans.26 The definition of the omni group
as defined by the NEW Soul study was used to identify participants who followed an
omnivorous diet that emphasized minimally-processed foods from plants, lean meats,
vegetable oils and low-fat dairy products (Table 4.4).26
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Table 4.4 NEW Soul Study- Definition of Study (Dietary) Groups26
VEGAN

OMNI

Dietary
Recommendations

Emphasized minimallyprocessed whole foods from
plants, no added oils, no dairy
and meeting daily protein
requirements through nuts,
seeds and beans.

Emphasized
minimally-processed
foods from plants,
lean meats, vegetable
oils and low-fat dairy
products

Whole Grains

6 servings (mostly whole
grains)

6 servings (mostly
whole grains)

Legumes/Beans

1- 1 ½ cups daily

½ cup – 1 cup daily

Nuts/Seeds

1 tbsp daily

1 tbsp daily

Fruit

2-4 servings daily

2-4 servings daily

Vegetables

3-5 servings (including green
leafy vegetables)

3-5 servings
(including green leafy
vegetables)

Animal Protein

None

3-5 oz. daily of lean
meats (nonprocessed)
Additional 2 servings
of fish each week
No more than 2 eggs
each week/unlimited
egg whites

Dairy

None

2-3 servings of lowfat dairy each day

68

Study Design and Methods of Analysis
A cost effectiveness analysis approach was utilized to compare costs in relation to
weight loss of the NEW Soul Study’s vegan group and omni group. Primary data
collection methods were utilized for this study.
Weight Loss
Weight loss has been previously used to determine power in NIH-funded dietary
intervention trials.28 Weight was collected at baseline and 12 months. A calibrated digital
scale (Healthometer®model 500 KL, McCook, IL) was used to collect participant’s
weight. Two measurements each time were taken and averaged.
Costs
Total costs of the intervention were calculated from a societal perspective. This
perspective includes aspects of non-health effects that provide insight into participant’s
net benefits or costs associated with the intervention.44 Total Costs = Costs to deliver the
intervention (ingredients for cooking demonstrations, meals) + participants’ average cost
of weekly groceries + average weekly costs of dining out. Cooking demonstration and
meal costs to deliver the intervention were collected and totaled from accounting reports
from year one for each diet group and averaged for each diet group. Literature has
determined a connection between costs of food, diet quality, and obesity and particularly
and advocates for the need to identify dietary patterns that are rich in nutrients and
affordable in order to reduce health and nutrition disparities. 27,33 Therefore, participants’
average cost of weekly groceries and dining out was collected at baseline and 1-year
assessments periods. Total costs will be divided by the number of total participants from
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each diet group. Table 4.5 contains a breakdown of the total cost of the vegan and omni
diet interventions over 12 months and difference in costs between the two.
ICER Interpretation
ICER is calculated by the cost differences between the vegan and omni diet
groups divided by the weight loss difference between the vegan and omni diet groups. A
cost effectiveness plane is used to interpret the ICER.31 The horizontal axis characterizes
the difference in effect between the vegan diet intervention and the alternative (omni diet
intervention).31 The vertical axis characterizes the difference in costs; if the ICER falls in
quadrants II or IV of the cost effectiveness plane, then the choice between whether the
vegan diet intervention or the omni diet intervention is more cost effective is without
question.31 The ICER falls in Quadrant II and is interpretated as the vegan diet group
being more effective and less costly than the omni diet intervention.31 That would mean
that the diet group intervention of interest dominates the alternative. If the ICER falls in
quadrant IV, then the opposite applies- the alternative dominates the diet group
intervention of interest. If the ICER falls within quadrants I or III, then the choice of the
intervention is based on the maximum cost effectiveness ratio that the decision maker is
willing to accept.31
Sensitivity Analysis
Probabilistic sensitivity analysis is required in guidelines for cost effectiveness
analysis to address uncertainties in the model. 28 Therefore, a Monte Carlo probabilistic
sensitivity analysis will be conducted to assess the robustness of the findings by
examining what can potentially happen and the likelihood of each outcome in order to
ensure that the results are acceptable for decisions related to scaling up this intervention
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in clinical and community settings.38 Additionally, in relation to a clinical study, it is
common that some participants have much higher costs that have more of an effect on the
mean costs, and skew the distribution.31
A detailed literature review was conducted by Mihaylova and colleagues to
describe alternative methods that can be used and three in particular were recommended:
ordinary least squares (OLS) regression; OLS with transformation to the log scale and
bootstrapping.154 The OLS method is based on normal distribution but estimates of mean
weight loss can be sensitive to extreme values for individual level participant costs. The
OLS with transformation method can be used when the probabilities are larger than those
of the exponential distribution.31 Since our study consisted solely of individual patientlevel data, the bootstrapping method is the more appropriate non-parametric alternative
for this study to describe the distribution of possible mean values of weight loss.31 This
method uses resampling from the data with replacements to produce a practical estimate
of the sampling distribution of mean costs.31 10,000 bootstrap samples were created to
show the uncertainty and acceptability curve. By repeatedly drawing a random sample
with replacement, a scatter plot of 10,000 bootstrapped incremental cost effectiveness
ratios, this produced estimates of the likelihood that the vegan diet intervention was cost
effective compared to the omni diet intervention based on the $50,000 - $150,000 US
willingness to pay threshold.
Among 105 participants, there are 53 in the omni diet group and 52 in the vegan
diet group. For bootstrap sampling, 53 random samples were drawn from the omni diet
group with replacements. The median cost change from baseline to 12 months (Cost
change_Omni) and mean weight loss from baseline to 12 months (Cost change_Vegan)
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were calculated and saved from this bootstrap sample. Cost difference and weight loss
difference between the two diet groups were also calculated.
Cost difference = Cost change_Vegan -Cost change_Omni
Weight loss difference = Weight loss_Vegan - Weight loss_Omni
ICER =

Cost difference
Cost change_Vegan − Cost change_Omni
=
Weight loss difference
Weight loss_Vegan − Weight loss_Omni

This will generate one ICER result based on one bootstrap sample. After
repeating the above process for 10,000 times, we obtained 10,000 bootstrapped ICER. A
scatter plot was created to display the distribution of ICER.
Acceptability Curve
The acceptability probability was estimated as the proportion of accepted ICER
out of the 10,000 ICER samples. The willingness to pay is based on 1.84 GDP per capita
($50,000) to 2.76 GDP per capita ($150,000), which is reflective of literature used to
assess willingness to pay in the United States.136 By increasing the willingness to pay,
acceptance probability values can be estimated. An acceptability curve can then be
plotted with the x axis representing the willingness to pay per 1 pound of weight loss and
the y axis representing the estimated acceptance probability.
Quality of Life Measurements
Quality of life (QOL) was measured using the SF-12, which includes 12 questions
(Q). These 12 questions can be grouped in to 8 domains of general health (Q 1), physical
functioning (Q 2-3), limitations in physical role functioning of physical health (Q 4-5),
limitations in emotional problems (Q 6-7), pain (Q 8), mental health (Q 9-10), vitality (Q
11) and social functioning (Q 12).38
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There are two steps to calculate QALY: 1) SF-12 must be converted into SF-6D
health state classification system; and 2) utility scores must be estimated based on SF-6D
classification. A search of the literature revealed two studies (2004, 2020) using two
different methods to calculate utility.38,45 Both methods will be applied to calculate
QALY and the distribution of the results from the two methods will be compared.
In order to classify SF-12 responses, the number of dimensions is reduced from
eight to six by excluding the general health item and combining the role limitation
dimensions (physical and emotional).38 By using SF-6D (2004), Q2 was selected for
physical functioning domain; Q5 and Q6 were combined into 4 levels for role functioning
(You have no problems with your work or other regular daily activities as a result of your
physical health or any emotional problems; You are limited in the kind of work or other
activities as a as a result of your physical health; You are limited in the kind of work or
other activities as a as a result of emotional problems; You are limited in the kind of work
or other activities as a as a result of your physical health and accomplish less than you
would like as a result of emotional problems ); Q8 was selected for pain, Q10 was
selected for mental health, Q11 was selected for virality and Q12 was selected for social
functioning.
In the 2020 paper, Short Form-6 Dimensions version 2 (SF-6Dv2), an updated
version of the SF-6D that addresses limitations, was developed to classify responses from
SF-12.45 Questions selected using the SF-6Dv2 (2020) paper were the same as SF-6D
(2004), except that Q4 and Q6 was combined into 5 levels for role functioning. Details
are presented in Table 4.5.
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Table 4.5- SF-12 Domain and Question Classification for SF-6D and SF-6Dv2

SF-12 Domains/items

Summary of contents

Response levels

Selected
for SF6Dv2
(2020
paper)

Selected
for SF6D
(2004
paper)

In general, would you say that your health
is

1 - Excellent; 2 - Very good; 3 Good; 4 - Fair; 5 - Poor

×

×

√
(3 out of 5
levels
match)

√

×

×

1 - All of the time; 2 - Most of
the time; 3 - Some of the time; 4
- A little of the time; 5 - None of
the time

√

×

1 - All of the time; 2 - Most of
the time; 3 - Some of the time; 4

×

√

General Health
Q1
Physical functioning
74
Q2
Q3
Role functioning
(physical health)

Q4

Q5

Moderate activities, such as moving a
table, pushing a vacuum cleaner, bowling,
or playing golf
Climbing several flights of stairs
During the past 4 weeks, how much of the
time have you accomplished less than you
would like as a result of your physical
health
During the past 4 weeks, how much of the
time were you limited in the kind of work
or other regular daily activities you do as a
result of your physical health

1 - Yes, limited a lot; 2 - Yes,
limited a little; 3 - No, not
limited at all
1 - Yes, limited a lot; 2 - Yes,
limited a little; 3 - No, not
limited at all

- A little of the time; 5 - None of
the time
Role functioning
(emotional problems)

Q6

Q7

During the past 4 weeks, how much of the
time have you accomplished less than you
would like as a results of any emotional
problems, such as feeling depressed or
anxious
During the past 4 weeks, how much of the
time did you do work or other regular
daily activities less carefully than usual as
a result of any emotional problems, such
as feeling depressed or anxious
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1 - All of the time; 2 - Most of
the time; 3 - Some of the time; 4
- A little of the time; 5 - None of
the time

√

√

1 - All of the time; 2 - Most of
the time; 3 - Some of the time; 4
- A little of the time; 5 - None of
the time

×

×

1 - Not at all; 2 - A little bit; 3 –
Moderately; 4 - Quite a bit; 5 Extremely

√
(5 out of 6
levels
match)

√

×

×

√

√

Pain

Q8

During the past 4 weeks, how much did
pain interfere with your normal work,
including both work outside the home and
housework

Mental health

Q9

How much of the time during the past 4
weeks have you felt calm and peaceful

Q10

How much of the time during the past 4
weeks have you felt downhearted and
depressed

1 - All of the time; 2 - Most of
the time; 3 - Some of the time; 4
- A little of the time; 5 - None of
the time
1 - All of the time; 2 - Most of
the time; 3 - Some of the time; 4
- A little of the time; 5 - None of
the time

Vitality

Q11

How much of the time during the past 4
weeks did you have a lot of energy

1 - All of the time; 2 - Most of
the time; 3 - Some of the time; 4
- A little of the time; 5 - None of
the time

√

√

During the past 4 weeks, how much of the
time has your physical health or emotional
problems interfered with your social
activities like visiting with friends or
relatives

1 - All of the time; 2 - Most of
the time; 3 - Some of the time; 4
- A little of the time; 5 - None of
the time

√

√

Social functioning

Q12
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For step two, the utility score was calculated based on SF-6D and SF-6Dv2. In the
2004 paper using SF-6D, four models (algorithms) to calculate utility were reported in
the literature. 38 Models 1 and 2 represent the algorithms to calculate utility based on
classifying responses from the SF-36. Models 3 and 4 represent the algorithms to
calculate utility based on (SF-12). Model 4 was utilized for this study because it was
determined in the literature to be the more consistent and preferred model because it does
not include variables that are not significant at p <0.05.38 Levels of each dimension in
Model 4 were aggregated if there were any inconsistencies.38 The SF-6Dv2 classification
presents six models of algorithms to calculate utility that were tested.45 Results indicated
Model 3 as the recommended algorithm to estimate QALYs because of its efficient
design using established experimental design procedures and due to the model being
ordered within dimensions, where increasing severity results in a decrease in utility.45
However, due to its recent results, this model has not been widely tested in US
populations with AA adults presenting with overweight/obesity. Both methods were used
to calculate utility and the distribution of utility score estimates.
Algorithms for each are listed in Table 4.6. Our study participants completed SF12 version 1 and there are 3 levels for physical functioning and 5 levels for pain. Our
modified coefficients to estimate utility for physical function are: 0 (Limited in vigorous
activities not at all); -0.034 (Limited in moderate activities a little); and -0.092 (Limited
in moderate activities a lot). For pain: 0 (No pain); -0.076 (Very mild pain); -0.139
(Moderate pain); -0.46 (Severe pain); and -0.62 (Very severe pain). The range of utility
scores by the SF-6Dv2 algorithm may exceed the 0-1 range. To account for this, we will
cap the QALY at zero for any values below zero.
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Table 4.6- SF-6D & SF-6Dv2 Utility Algorithms
SF-6Dv2
Classification
System (2020)
Physical
functioning (5
levels)
Limited in
vigorous
activities not at
all
Limited in
vigorous
activities a little
Limited in
moderate
activities a little
Limited in
moderate
activities a lot
Limited in
bathing and
dressing a lot
Role functioning
(5 levels)

Match
with
SF-12

SF-6D
Classification
System (2004)
Physical
Model
functioning (3
Coefficients
levels)

Yes

0

No

-0.019

Yes

-0.034

Yes

-0.092

No

-0.186

Accomplish less
than you would
like none of the
time

Yes

0

Accomplish less
than you would
like a little of the
time

Yes

-0.039

Accomplish less
than you would
like some of the
time

Yes

-0.055

Your health does
not limit you in
moderate activities

Your health limits
you a little in
moderate activities
Your health limits
you a lot in
moderate activities

Match
Model
with
Coefficients
SF-12
Yes

0

Yes

0

Yes

-0.045

Role functioning
(4 levels)
You have no
problems with your
work or other
regular daily
activities as a result Yes
of your physical
health or any
emotional
problems
You are limited in
the kind of work or
other activities as a Yes
as a result of your
physical health
You are limited in
the kind of work or
Yes
other activities as a
as a result of
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0

-0.063

-0.063

Accomplish less
than you would
like most of the
time

Accomplish less
than you would
like all of the
time
Social
functioning (5
levels)

Yes

-0.099

Yes

-0.102

emotional
problems
You are limited in
the kind of work or
other activities as a
as a result of your
physical health and
accomplish less
than you would
like as a result of
emotional
problems

-0.063

Yes

0

Yes

-0.063

Yes

-0.066

Yes

-0.081

Yes

-0.093

Yes

0

Social functioning
(5 levels)

Social activities
are limited none
of the time

Yes

0

Social activities
are limited a little
of the time

Yes

-0.008

Social activities
are limited some
of the time

Yes

-0.029

Social activities
are limited most
of the time

Yes

-0.103

Social activities
are limited all of
the time

Yes

-0.137

Yes

0

Your health limits
your social
activities none of
the time
Your health limits
your social
activities a little of
the time
Your health limits
your social
activities some of
the time
Your health limits
your social
activities most of
the time
Your health limits
your social
activities all of the
time
Pain (5 levels)
You have pain that
does not interfere
with your normal
work (both outside

Pain (6 levels)
No pain

Yes
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Very mild pain

Yes

-0.076

Mild pain

No

-0.097

Moderate pain

Yes

-0.139

Severe pain

Yes

-0.46

Very severe pain

Yes

-0.62

the home and
housework) at all
You have pain that
interferes outside
with your normal
work (both outside
the home and
housework) a little
bit
You have pain that
interferes outside
with your normal
work (both outside
the home and
housework)
moderately
You have pain that
interferes outside
with your normal
work (both outside
the home and
housework) quite a
bit
You have pain that
interferes outside
with your normal
work (both outside
the home and
housework)
extremely
Mental health (5
levels)
You feel
downhearted and
low none of the
time
You feel
downhearted and
low a little of the
time

Mental health (5
levels)
Depressed or very
nervous none of
Yes
the time

0

Depressed or very
nervous a little of Yes
the time

-0.026

Depressed or very
nervous some of
Yes
the time

-0.086

You feel
downhearted and
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Yes

0

Yes

-0.042

Yes

-0.077

Yes

-0.137

Yes

0

Yes

-0.059

Yes

-0.059

Depressed or very
nervous most of
Yes
the time
Depressed or very
nervous all of the Yes
time
Vitality (5 levels)

-0.236

-0.324

Worn out none of
the time

Yes

0

Worn out a little
of the time

Yes

-0.015

Worn out some of
Yes
the time

-0.015

Worn out most of
the time

Yes

-0.08

Worn out all of
the time

Yes

-0.121

Worst

low some of the
time
You feel
downhearted and
low most of the
time
You feel
downhearted and
low all of the time
Vitality (5 levels)
You have a lot of
energy all of the
time
You have a lot of
energy most of the
time
You have a lot of
energy some of the
time
You have a lot of
energy a little of
the time
You have a lot of
energy none of the
time
Worst

-0.084
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Yes

-0.113

Yes

-0.134

Yes

0

Yes

-0.078

Yes

-0.078

Yes

-0.078

Yes

-0.106
-0.077

Change in QALY
QALY change from baseline to 12 months was calculated based on the change in
utility scores multiplied by the duration of the study (1 year). Participants in the NEW
Soul Study were asked to recall their health conditions during the past 4 weeks at
baseline and 12 months. We believe the estimated utility score during the past 4 weeks
for each measurement period appropriately reflects the health condition of our study
participants.
Differences-in-Differences (DD) Regression of QALY
Difference-in-differences (DD) model is commonly used in health services
research.135 A difference-in differences (DD) regression analysis is able to directly
estimate the effect difference (e.g. weight loss difference, QALY gain between 2 diet
groups) while controlling for age, sex, education, employment, class attendance, and
physical activity.
Y = b0 + b1*t + b2*diet group + b3*diet group*t + b4*age+ b5* sex + b6*education + b7
*employment + b8 *class attendance + b9*physical activity + b10* cohort
Data is converted into “long” format. Each participant has two measures: one at baseline
(which was denoted by t=0) and the other at 12 months (which was denoted by t=1). To
address the within subject correlation, repeated measures regression was fitted using the
unstructured covariance matrix. Least square means were estimated. The coefficient on
the interaction term b3 provides the estimate of the effect difference between the vegan
and omni diet groups.
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All analysis was conducted using SAS. DD regression with repeated measures is fitted
using the MIXED procedure.
Results
Cost Effectiveness Analysis
Since the distribution of cost is not normally distributed, the median of total cost
was reported. A total costs savings of $747.51 was observed in the omni group
intervention at 12 months from baseline. A total costs savings of $876.34 was observed in
the vegan group intervention at 12 months from baseline. Each of the interventions
resulted in total costs savings, the largest savings was observed in the vegan diet group
intervention. The difference in cost savings between the vegan and omni diet
interventions was $128.82 (Table 4.7).
An average weight loss of 6.18 pounds was observed in the omni group
intervention between baseline and 12 months. An average weight loss of 6.22 pounds was
observed in the vegan group intervention between baseline and 12 months (Table 4.7).
Normality assumption checks were also performed and satisfied based on results from QQ plot distributions (Figure 4.1). Each of the interventions resulted in significant weight
loss (Table 4.8). The largest savings was observed in the vegan group intervention,
however the difference-in-differences (DD) in weight loss between the diet group
interventions was not statistically significant (Table 4.9).
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Table 4.7- CEA findings to calculate change in total costs
OMNI (n=53)

84

At baseline:
Cost of groceries
Cost of dining out
($)
Total
At month 12:
Cost of groceries
Cost of dining out
($)
Costs for cooking
demonstrations
Total
Cost change in
month 12,
compared to
baseline

Difference in
median cost
(Vegan - Omni)

VEGAN (n=52)

mean
4530.87

Median
4160

p25
2600

p75
5200

mean
median
4802.25
3640

p25
2600

p75
7150

2830.57

1820

1040

3120

2802

2002

1040

4550

7361.43

6760

4160

8580

7604.25

5200

3900

10400

5668

5200

3120

7800

5005

3900

2600

5720

1354.94

1040

0

1560

1749

1300

520

2600

32.49

32.49

32.49

32.49

33.66

33.66

33.66

33.66

7055.43

6012.49

3932.49

8872.49 6787.66

5233.66

3933.66

8353.66

-306

-747.51

-2567.51 1488.49 -816.59

-876.34

-2748.34 1593.66

=(-876.34)-(747.51)=-128.83

Table 4.8- CEA findings to calculate average weight loss
Weight
(Lbs)

mean ± sd

Normality
assumption
check

VEGAN
(n=52)

OMNI (n=53)
(Min,
Max)

mean ± sd
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( 129.41 ,
357.81 )

224.35 ± 40.4

( 150.8 ,
304.24 )

Avg
215.97 ±
Weight at
49.97
month 12

( 124.12 ,
376.77 )

218.13 ±
41.75

( 148.59 ,
298.95 )

( -41.78 ,
19.84 )

-6.22 ± 12.86

t Tests

(Min, Max)

Avg
222.15 ±
Weight at
49.52
baseline

Avg
Weight
loss
(change
in weight
-6.18 ± 13.05
in month
12,
compared
to
baseline

Equality of
Variances
Tests check

( -44.75 ,
28.66 )

F value=1.5,
numerator
satisfied based DF/denominator
on Q-Q plot
DF=52/51,
p=0.1477,
pooled t test
F value=1.43,
numerator
satisfied based DF/denominator
on Q-Q plot
DF=52/51,
p=0.2012,
pooled t test

t value=-0.25,
DF=103, p=0.8033

t value=-0.24,
DF=103, p=0.8107

F value=1.03,
numerator
satisfied based DF/denominator t value=0.02,
on Q-Q plot
DF=52/51,
DF=103, p=0.986
p=0.9176,
pooled t test
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Figure 4.1- Q-Q Plots for average weight at baseline, 12 months and weight difference

Table 4.9- CEA findings to calculate DD of average weight loss
Weight Loss
At
Weight
At
(weight at month
month
Change (lbs) baseline
12 - weight at
12
baseline)

Test

Estimate

Standard
error

Estimate

Standard
error

Estimate

Standard
DF
error

t Value Pr > |t|

OMNI

233.57

9.1734

227.4

9.1734

-6.1771

1.7795

103

-3.47

0.0008

VEGAN

231.69

8.7947

225.46

8.7947

-6.2217

1.7965

103

-3.46

0.0008

-0.0446

2.5286

103

-0.02

0.986
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DD in weight
loss
(vegan - omni)

With regards to intervention costs per pound of weight loss, the incremental cost
effectiveness ratio is noted below (Table 4.10).
Table 4.10- CEA ICER results
Weight
Difference
Mean
OMNI (n=53)
VEGAN (n=52)
Vegan-Omni
difference

ICER =

-6.1771
-6.2217
-0.0446

Cost
difference
Standard
Median
error
1.7795
-747.51
1.7965
-876.34
2.5286

-128.83

ICER

2888.57

Cost difference
−128.83
=
= $2,888.57 BCD BEFGH EI JCKLℎN OEPP
Weight loss difference
−0.0446

Compared to the omni group intervention, the vegan group intervention is
dominate (cost effective) due to greater weight loss at a lower cost, positioning it in the
quadrant (II) on the cost effectiveness plane.

Figure 4.2 Cost Effectiveness Plane of ICER
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Figure 4.3 represents the scatter plot of bootstrapped ICER based on 10,000
samples. The variance of the ICER is large, which might be attributed to the small
difference in weight loss between the vegan and omni diet groups.

Figure 4.3- Monte Carlo (Bootstrap) Scatter Plot of BootStrapped ICER (n= 10000)
Acceptability Curve
The acceptability probability was estimated as the proportion of accepted ICER
out of the 10,000 ICER samples. The x axis represents the willingness to pay in the
United States- 1.84 GDP per capita ($50,000) to 2.76 GDP per capita ($150,000.136 The y
axis represents the estimated acceptance probability. By increasing the willingness to
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pay, acceptance probability was around 43% indicating that as the willingness to pay
increases, the probability that the ICER is below the maximum willingness to pay does
not change much (Figure 4.2).

Figure 4.4- Monte Carlo (Bootstrap) sensitivity analysis acceptability curve
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The estimated utility scores based on both algorithms had a similar distribution (Table
4.11) and the density plot of utility scores was plotted at baseline in Figure 4.5 and at 12
months in Figure 4.6.

Figure 4.5-Distribution of Utility Score Estimates at Baseline By SF-6D and SF-6Dv2
Algorithms

Figure 4.6-Distribution of Utility Score Estimates at 12 months by SF-6D and SF-6Dv2
Algorithms
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Table 4.11-Distribution of Utility Score Estimates at Baseline and 12 by SF-6D and SF6Dv2 Algorithms
Algorithm
SF-6D
(2004
paper)

SF-6Dv2
(2020
paper)

Time

N

Mean

SD

Median

p25

p75

min

max

At
baseline

105

0.79

0.11

0.8

0.7

0.86

0.42

0.92

At
month
12

105

0.8

0.12

0.82

0.71

0.92

0.47

1

At
baseline

105

0.81

0.18

0.85

0.76

0.93

0

0.99

At
month
12

105

0.76

0.25

0.87

0.68

0.91

0

0.99

QALY change from baseline to 12 months was calculated based on the change in
utility scores multiplied by the duration of the study (1 year) based on SF-6D results
(Table 4.12) and SF-6Dv2 (Table 4.13). Participants in the NEW Soul Study were asked
to recall their health conditions during the past 4 weeks at baseline and 12 months. We
believe the estimated utility score during the past 4 weeks for each measurement period
appropriately reflects the health condition of our study participants. Estimated utility
scores from both algorithms are close to each other, however results calculated from SF6Dvs are not normally distributed, so QALYs gained based on the SF-6D algorithm is
used for the DD regression analysis, as these results are normally distributed.

92

Table 4.12- QALYs Gained Based on Calculations from SF-6D Utility Scores
QALY
(2004)

OMNI
(n=53)
mean
± sd

Normality
Equality of Variances
assumption
Tests check
check

VEGAN
(n=52)
(Min,
Max)

mean ±
sd

Tests

(Min,
Max)
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Utility Score
at baseline

0.77 ±
0.11

( 0.51 ,
0.92 )

0.8 ±
0.12

( 0.42 ,
0.92 )

Utility Score
at month 12

0.79 ±
0.13

( 0.47 ,
0.92 )

0.8 ±
0.12

( 0.48 , 1 )

QALY
gained in
month 12,
compared to
baseline

0.02 ±
0.09

( -0.2 ,
0.23 )

0.01 ±
0.13

( -0.32 ,
0.27 )

F value=1.28,
satisfied
numerator
based on Q- DF/denominator
Q plot
DF=51/52, p=0.3729,
pooled t test
F value=1.09,
satisfied
numerator
based on Q- DF/denominator
Q plot
DF=52/51, p=0.7536,
pooled t test
F value=1.92,
satisfied
numerator
based on Q- DF/denominator
Q plot
DF=51/52, p=0.0206,
Satterthwaite t test

t value=-1.08, DF=103,
p=0.2843

t value=-0.58, DF=103,
p=0.5607

t value=0.46, DF=92.68,
p=0.6496

Table 4.13- QALY Gained Based on Calculations from SF-6Dv2 Utility Score
QALY
(2020)

OMNI (n=53)

Normality
assumption
check

VEGAN (n=52)

mean median p25

p75

mean median p25

Wilcoxon
rank-sum
test

p75
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Utility score
0.81
at baseline

0.84

0.76 0.91 0.82

0.87

0.77

0.95 Not satisfied

p=0.3458

Utility score
0.76
at month 12

0.87

0.65 0.91 0.75

0.86

0.72

0.91 Not satisfied

p=0.9898

QALY
gained in
month 12,
-0.05
compared to
baseline

-0.02

0.05 -0.06
0.12

0

-0.08

0.04 Not satisfied

p=0.9591

A difference-in differences (DD) regression analysis was conducted to explain the
difference in average QALY (based on utilities scores from SF-6D) between diet groups
while controlling for age, sex, education, employment, class attendance, and physical
activity.
Y = b0 + b1*t + b2*diet group + b3*diet group*t + b4*age+ b5* sex + b6*education + b7
*employment + b8 *class attendance + b9*physical activity + b10* cohort
H0 for 2b & 2c: Avg QALYVegan=Avg QALYOmni
HA for 2b & 2c: Avg QALYVegan ≠Avg QALYOmni
There was no statistically significant difference in average QALY gain between
diet groups while controlling for age, sex, education, employment, class attendance, and
physical activity. Therefore, we fail to reject the null hypothesis. Table 4.14 shows the
results from the least squares means estimate from the DD regression model. The DD in
QALY between the vegan and omni diet groups was not statistically significant.
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Table 4.14- Solution for Fixed Effects based on SF-6D DD Models
Effect
Intercept
t
Diet Group
t*Diet_Group

Cohort

94
103
.
103
.

t Valu
e
7.95
1
.
0.6
.

0.02132

103

-0.46

0.6485

0

.

.

.

.

0

.

.

.

.

0

.

.

.

.

0.0157
0
0.00235
7
0.03902
0
0.02652
0.01939
0
0.00104
1

0.02188
.
0.00119
5
0.03041
.
0.02833
0.02368
.
0.00075
5

103
.

0.72
.

0.4747
.

103

1.97

0.0513

103
.
103
103
.

1.28
.
0.94
0.82
.

0.2023
.
0.3514
0.4148
.

103

1.38

0.1709

High school or
equivalent,
Some college

0.00962
5

0.02802

103

0.34

0.7319

College

0.00424
7

0.02414

103

0.18

0.8607

0

.

.

.

.

-0.02078
0

0.03219
.

103
.

-0.65
.

0.5201
.

Levels
At month 12
At baseline
Vegan
Omni
At month
12*Vegan
At month
12*Omni
At
baseline*Vega
n
At
baseline*Omni
1
2

Age
Sex
Physical activity

Male
Female
High
Low
Moderate

Class_Attendanc
e
Education

Employment

Advanced
degree
Unemployed
Employed

0.5482
0.01508
0
0.01377
0

Standard
Error
0.06899
0.01501
.
0.02295
.

-0.00975

Estimate

96

DF

Pr > |t|
<.0001
0.3174
.
0.55
.

Table 4.15- SF-6D Least Squares Means Estimate from DD Models Adjusted for Covariates (Repeated Measures Reg Results)

QALY

At
baseline
Estimate

OMNI
VEGAN
DD in
qaly
(vegan omni)

0.7889
0.8027

At
month
12

QALY
( at
month
12 - at
baseline)

Standard
Standard
Estimate
Estimate
error
error
0.02269 0.804
0.02269 0.01508
0.02187 0.808
0.02187 0.005327
-0.00975

Test
Standard
DF t Value Pr > |t|
error
0.01501
103
1 0.3174
0.01515
103
0.35 0.7258
0.02132

103

-0.46 0.6485
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Discussion
This study sought to determine the cost effectiveness of a culturally tailored
dietary intervention, which included participants being assigned to either a vegan diet
group or an omni diet group. The vegan diet group demonstrated more weight loss at less
cost, compared to the omni diet group and was determined to be the clear choice
(dominant) of the interventions.
The findings from this economic evaluation supplement the findings from
economic analysis of the Food Choice at Work Study and Postpartum Diet that suggests
the importance of opportunities for community stakeholders, policy makers, and health
care providers to recommend programs that promote weight loss through dietary changes.
Additionally, results complement the findings in the literature that reveal that healthful
plant-based are associated with prevention of chronic disease, healthier body weights,
and lowering CVD risk factors for AAs. 86–91,117–122
When considering the second outcome measure of the DD in QALY between the
vegan and omni intervention, there was no statistically significant difference. Generally
speaking, both diet groups experienced a small increase in QALY from baseline to 12
months; however, the values were not statistically significant.
Advising future community-based approaches and population health decision
making requires regard of cultural acceptability, costs, and benefits. Because this
analysis was conducted from a societal perspective, it provides the best indication of
overall cost effectiveness of the interventions and is very useful for decisions related to
the allocation of resources.30,155
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From a health services research perspective, there is a critical need to identify and
implement culturally relevant research-based nutrition interventions that are also
financially sustainable to combat CVD within the AA population. Existing literature
supports the novel theoretical concept of applying a cost effectiveness analysis (CEA) to
dietary interventions.18–25 This study suggests that a vegan diet can potentially offer the
best value, from a societal perspective, in terms of weight loss and dietary
recommendations that are culturally acceptable and less costly for those who present with
CVD risk factors.
The primary strength of this economic evaluation is that it is the only study to our
knowledge that evaluates the cost effectiveness of a culturally-tailored dietary
intervention, comparing a vegan and omni diet, for an all AA study population presenting
with CVD risk factors. The reported QALYs gained is another strength of this study. The
Medical Research Council advises that interventions shown to be effective in improving
health are more likely to be scaled up for future implementation if results are relevant to
decision makers.156 Public health professionals, policy makers and medical providers
observe the impact of CVD and other chronic disease disparities on quality of life,
community health and healthcare spending and desire solutions. This study also
minimized the need for assumptions because it included primary data collection measures
and prospective cohort study with randomization.
This study is not without limitations. This cost effectiveness analysis involves a
comparative of two dietary “courses of action” of the NEW Soul study that aim to reduce
obesity, a major CVD risk factor. The difference in costs of the vegan and omni diets s
are compared with the difference in outcomes. However, there are some questions that a
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CEA of the NEW Soul Study cannot answer. This study is subject to limitations because
it is limited in scope to the NEW Soul study specifically and does not take into account
all potential dietary patterns to address CVD prevention. Additionally, another limitation
of this analysis is that it does not include all outcomes associated with the intervention,
such as lipid panel results to assess cholesterol levels and blood pressure. Time spent
shopping and meal prepping were not assessed at baseline, therefore these costs were
imputed based on data collected for these measures in the literature. Future studies should
assess these measures at all time points. Selection bias can also occur since all
participants volunteered for this study. Participants may share social characteristics that
are different from others who did not volunteer to participate in this study. Furthermore,
life changing events, such as, but not limited to changes in: income, household size and
marital status. However, we do not expect that these changes will be different between
groups.
Threats to the validity of the study include: attrition; data underreporting or
overreporting; and measurement error. Attrition is a threat to the validity of this study,
because not all participants participated in the 12 month assessment where weight was
collected. Data underreporting or overreporting may also have been present, as
participants may have underreported or overreported the average amount of money they
spent on groceries and dining out, and/or their time spent shopping and preparing food. If
this data was underreported or overreported, it would not reflect the true costs associated
with the diet group that is used to calculate the ICER and ICUR. Measurement error may
have also resulted due to participants answering questions retrospectively and
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inaccurately recalling information. Additionally, measurement error could have resulted
during the collection of weight and/or during the entry of that data.
Significant measures were taken by the NEW Soul Staff to assure the reliability
and validity of the data. These measures included: frequent communication with
participants to maximize participation in assessments to collect weight; helpful text
within the surveys to ensure that participants understood survey questions that were
designed with an upper elementary reading level; and collecting two weight
measurements that were recorded and triple checked upon entering the data.
Conclusion
While this study presents a cost effective intervention for AAs presenting with
heart disease risk factors, that considers direct and indirect costs, future research should
include data collection beyond 12 months in order to further assess health effects such as
lipid panel results to assess cholesterol levels and blood pressure that were not
represented in this study.
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CHAPTER 5
MANUSCRIPT TWO
CONDUCTING CLINICAL ASSESSMENTS FOR THE NUTRITIOUS EATING
WITH SOUL STUDY DURING COVID-19 & ITS IMPACT ON WEIGHT LOSS

1

Wilson, M.J., Crouch, E., Turner-McGrievy, B., Chen, B., Hung, P.…To be submitted.
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Abstract
Background
Historically, African Americans have been underrepresented in research. The Nutritious
Eating With Soul (NEW Soul) Study is the first of its kind to recruit an African American
(AA) only study group to examine heart disease prevention via a clinical trial to examine
changes in heart disease risk factors across two cohorts who are randomly assigned to a
plant-based vegan diet or low-fat omnivorous diet. The purpose of this study is to
describe the clinical assessment methods implemented by the NEW Soul Study, in order
to conduct research in a safe environment with special emphasis on methods used to help
mitigate the risk and spread of COVID-19 within an all-AA study population and to also
examine the impact that COVID-19 had on our study population’s weight loss.
Methods
University IRB approval was granted to resume in-person research based on established
protocol. Staff were tested for COVID-19 and trained on safety measures and social
distancing protocol to conduct assessments. Participants received a detailed account of
safety measures in place via personal phone calls, email and text message. Participants
completed a sign up for an individual time slot between 6am and 10am to complete the
assessment. Options for a full (weight, bp and bloodwork) or partial assessment (weight
and/or bp only) were provided based on the comfort level of participants. Partial
assessments were offered indoors or outdoors under a covered patio based on participant
preference. A COVID-19 symptom screening and temperature check was required, and
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personal protective equipment was required and provided to staff and participants prior to
entering the assessment location.
Findings
Across the two cohorts, full or partial assessment completion at 1-year prior to COVID19 and during COVID-19 fell within the 80th percentile: Cohort 1 pre COVID-19 (88%)
and Cohort 2 during COVID-19 (80%). The difference-in-differences in weight loss in
Cohort 1 (pre-COVID) and Cohort 2 (during COVID) resulted in a statistically
significant difference of 6.5 pounds.
Conclusions
Detailed COVID-19 protocol for conducting assessments and communication of this to
participants, along with staff training to execute assessment protocol were key to
conducting clinical assessments. In comparison to weight loss prior to the pandemic,
COVID-19 significantly impacted our participant’s weight loss.
Keywords: clinical assessment, COVID-19, dietary intervention, weight loss
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Introduction
During the COVID-19 pandemic, there has been increasing attention put on
patients with cardiovascular disease risk factors, such as hypertension, as these patients
are at a higher risk for developing more serious cases of COVID-19.157,158 Obesity has
also been linked to increased susceptibility to COVID-19 and a higher risk for
respiratory failure.158,159 The pandemic revealed that health disparities in the African
American community have become even more prominent; AAs, compared to nonHispanic White people, were disproportionately affected by COVID-19 (2.6 times higher
cases), were hospitalized 4.7 times more, and were 2.1 times more likely to die as a result
of the illness.146,147
Literature also suggested that quarantine and isolation disproportionately
impacted weight management, health behaviors and psychosocial health amongst
individuals in the US with obesity, regardless of COVID-19 illness status.148 Patients in
medical settings and public survey respondents consistently reported: spending more time
at home; hardships achieving/maintaining weight loss goals; decreased physical activity;
increased stress eating; decreased dietary restraint; and an increase in anxiety and
depression.148,149,150 A systematic review of the literature that included 36 studies
identified similar trends at the global level.153 However, a critical gap in knowledge about
the impact of COVID-19 on vulnerable populations remains, as African Americans were
largely underrepresented in these studies. Therefore, this study aims to examine
implemented research measures to help mitigate the risk and spread of COVID-19 during
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the NEW Soul Study’s clinical assessments, assessment completion rates, and the impact
of COVID-19 on weight loss for African American participants at high risk for CVD and
COVID-19 illness and mortality. We hypothesize that participants impacted by the
COVID-19 pandemic during 12-month assessments will experience reduced weight loss,
compared to participants not affected by the COVID-19 pandemic during 12-month
assessments.
Methodology
Study Design and Participants
African American adults (18-65 years of age) in the Midlands region of South
Carolina with overweight or obesity (BMI 25-49.9 kg/m2) who enrolled in Cohorts 1 and
2 of the Nutritious Eating With (NEW) Soul Study, a behavioral nutrition intervention,
were chosen for this study. All participants completed an online screening questionnaire
and follow-up phone screening to confirm eligibility criteria listed below.26
Table 5.1: NEW Soul Eligibility Criteria
Inclusion Criteria

Exclusion Criteria

Self-identify as African American

Following a vegan diet

Be between the ages of 18-65 years

Currently on medication for diabetes

Body Mass Index between 25-

Currently pregnant or breastfeeding or

49.9kg.m2

plan to become pregnant in the next 24
months

Live in Columbia, SC/Midlands area
Be able to attend all monitoring and
class visits
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Upon completion of the baseline assessment, participants were randomized to one of
two groups: the vegan group or the low-fat omnivorous diet group using a computer
program allocation sequence and stratified by gender and baseline BMI. The cohorts
were separated by one year. Cohort 1 began the study in May 2018 and Cohort 2 began
the study in June 2019. See Table 5.2 for summaries of participant enrollment for both
cohorts. See Table 5.3 for summaries of enrollment and randomization.
Table 5.2 Demographics of NEW Soul Study Cohort 1 & 2 Participants (N=159)
Cohort 1 (n=67)
N%
N

Characteristics
Gender

Cohort 2 (n=92)
N
N%

Female
Male

59
8

88.05
11.94

67
25

72.82
27.17

Hispanic or Latino
Not Hispanic or Latino
Unknown

1
66
0

1.50
98.50
0

1
91
0

1.09
98.91
0

Ethnicity

Age
Mean (SE)

47.7 (1.4)

Median (min, max) 50 (25, 65)

48.7 (1.1)
50 (25,
65)

Race
American Indian/Alaskan
Native
0
0
0
0
Asian
0
0
0
0
Nat Hawaiian/Other Pac
Islander
0
0
0
0
Black or African American
65
97.01
92
100
White
0
0
0
0
Other
0
0
0
0
African American and other
race
2
2.99
0
0
Unknown
0
0
0
0
**Note that all participants must self-identify as Black/African American to enroll in the
study, but participants may indicate more than one race.
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Table 5.3 NEW Soul Study Participant Enrollment and Randomization
Cohort 1
Cohort 2
Cohorts 1
Complete Data
Total
Total
&2
Cohorts 1 & 2
Enrolled @
Enrolled @
Combined
Combined
Baseline
Baseline
(Baseline & 12
months)
Omni Control
34
48
82
53
Vegan
33
44
77
52
Intervention
Total
67
92
159
105
Participants
(Female=59
(Female= 67
(Female=1 (Female = 88 Male
Male=8)
Male=25)
26
=17)
Male=33)
Definition of Study Groups
For the purposes of this study, study groups are defined as cohorts. Cohort 1 at 1year assessments was not affected by COVID-19. Cohort 2 at 1-year was affected by
COVID-19 (Table 5.4). See Table 5.5 for measurements collected during assessments.
Table 5.4 Definition of Study Groups

Affected by
COVID-19?

Cohort 1: 1year
assessments
(April 2019)

Cohort 2: 1-year assessments
(June-July 2020)

No
Assessments
occurred prior
to the
pandemic

Yes
Assessments occurred during the
pandemic
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Clinical Assessment Protocol During COVID-19
In response to the threat of COVID-19 on the health of the public, an executive
order from the South Carolina Governor’s office was issued and all system institutions of
the University of South Carolina were closed beginning March 16, 2021. University IRB
approval was granted to resume in-person research based on established protocol set forth
by NEW Soul supervisory staff for workers and participants. Workers hired to conduct
assessments were tested for COVID-19 and were trained both virtually and in-person on
safety measures and social distancing protocol. Staff training included proper
handwashing and mask wearing. Additionally, staff was trained on work shift check-in
procedures that included a temperature check and answering COVID-19 screening
questions prior to each shift to assess potential illness and exposure. Staff were also
trained on participant interaction and appointment check-in. Participants received a
detailed account of safety measures in place via phone calls, email and text message.
Table 5.5 Summary of All Measures Being Collected at 1-year Assessments
Cohort
Calendar month and year

Cohort 1
1 year
April 2019

Measure

Cohort 2
1 year
June-July
2020

Collected

Weight

X

x

Physical Activity (ActiGraph Accelerometer GT1M model)

X

---

Blood Pressure
Bloodwork (Fasting Lipids, Glucose, and Insulin)

X

x

X
X

x
x

X

-----

X

x

Body Fat (DEXA Scan)
Waist-to-Hip Circumference
Class Attendance and Use of
Intervention Components
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Table 5.6 COVID-19 Clinical Assessment Protocol
COVID Procedures
Participant Details
Assessment appointment
signup

Screening process to
determine the COVID-19
risk status of volunteers
and staff (e.g.
questionnaire regarding
health status, recent
travels, body temperature,
etc.).

Follow the signup genius
link to sign up for an
individual time slot between
6am and 10am to complete
your assessment. Options
for a full (weight, bp and
bloodwork) or partial
assessment (weight and/or
bp only) are available based
on your comfort level.
Please contact us with any
additional
requests/questions that you
might have so that we can
best accommodate you.
Upon arrival, participants
will sit in their car and call
the number sent to them via
the instruction sheet. A staff
member will respond and
ask them questions
regarding health status,
travel, and recent
exposures. This staff
member will also take their
temperature before allowing
them in the facility.

Staff Details
Review appointment
sign-ups and any
notes/requests from
participants. Provide
appointment
confirmation and send
reminders 2 days and 1
day prior to the
appointment. Call
participants if they do
not arrive within 10
minutes of their
scheduled appointment
time.
Pass PPE through the
window and instruct
participant to put on gear
prior to talking.
COVID-19 Screening
questions.
1) Have you recently had
a fever, cough, or
shortness of breath
within the last week?
Circle: Yes/No
2)Have you been around
anyone sick within the
last week?
Circle: Yes/No
If participant answers
“yes” to either one of
these questions, please
inform the participant
that in order to prevent
the spread of COVID-19,
that they will not be able
to complete the lab
assessment and that the
project manager will be

110

in touch to reschedule
your appointment.
Inform participant that
you must conduct a
temperature screening
prior to entry into the
building.

Social distancing
requirements

Use of Personal Protective
Equipment (PPE),
including what is required
and how it will be obtained

*If participant is running
a fever over 100 °F,
inform the participant
that in order to prevent
the spread of COVID-19,
that they will not be able
to complete the lab
assessment and that
Mary will be in touch to
reschedule their
appointment.
All participants will wait in Assist your assigned
their car to avoid any
participant in completing
overlap with other
all measurements (blood
participants. All participants pressure and weight).
and staff will be wearing a
Maintain 6 feet distance
mask and gloves. Each
outside of required
participant will be working contact for
with one specific staff
measurements.
member to minimize
contact.
All participants will be
wearing a face mask that
are provided by the study
and will be asked to wear
them prior to entering the
facility and remain wearing
them at all times. Gloves
will be available but are
optional. Hand sanitizer will
be provided throughout the
facility. All staff members
will also be wearing a face
mask and gloves. New
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Masks are required.
Gloves are required and
must be changed before
contact with each
participant. No eating or
drinking in the lab. A
morning break mid-shift
will be provided for
workers to properly
distance to consume
snacks outside of the lab.

gloves will be used between
participants.
Proper cleaning of
materials, equipment and
commonly touched areas
where the activities will
take place

Each room will be sanitized
between participants. Staff
will use new gloves
between participants. All
surfaces will be wiped
down with disinfectant
wipes. Extra attention will
be paid to commonly
touched surfaces like
doorknobs, handles, and
chairs. Participants and staff
will not be allowed to eat or
drink in the facilities.
Bathroom use will be
minimized, and the
bathroom will be sanitized
between use. Participants
should be discouraged from
touching surfaces; staff
should do things like open
and hold doors if possible.

Staff will clean
equipment and touched
surfaces prior to and
after measurements of
each participant.

Plan for scheduling visits
to avoid overlap in
appointments

All participants will be sign
up for a specific time in
advance. All participants
must arrive at their
designated time and will be
asked to wait in their
vehicle until we are ready
for them to enter the
facility, one participant at a
time. No one will be
allowed to enter a room
where another participant is
currently located or before
it has been sanitized.

If participants arrive late
or early to their
appointment, maintain
assisting only one
participant at a time in
the assessment area and
have participants wait in
their vehicle until the
area is clear of any other
participant.

If included in the subject
population, plans for
handling visits by

All participants with
Special notations will be
underlying health
included in participant’s
conditions will be instructed day-of file for any
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participants in high-risk
categories (older adults
and anyone with serious
underlying medical
conditions). Refer to CDC
guidance for a full list.

to contact us in advance.
We will provide them with
a list of conditions to notify
us about. Current
procedures should be
enough but knowing which
participants to specifically
look out for will allow us to
be extra cautious.

changes to procedures to
best accommodate the
participant. One onsite
supervisor will be
available to answer
questions, and the
project manager will
oversee lab operations
virtually via google
meet.

Study Design
Clinical assessment protocol during COVID-19 was established to help mitigate
the risk and spread of COVID-19 for NEW Soul participants. The overall percentage of
assessment completion for each cohort was utilized to understand assessment
participation before and during COVID-19 based on the safety measures put forth by the
NEW Soul Study staff. A quasi-experimental difference-in-differences (DD) study design
was utilized to compare average weight loss at 1-year assessments between Cohort 1 who
was not affected by the pandemic and Cohort 2 who was affected by the pandemic.
The dependent variable for the DD estimation was average weight loss. The
primary independent variable of interest was the status of the COVID-19 pandemic:
before or during. Participant demographic characteristics (age, sex, education group, and
employment) and intervention participation variables (class attendance and physical
activity) were included in the adjusted models based on their potential to impact weight
loss.162,163
Analytic Approach
All full (weight, blood pressure, bloodwork, dexa scan) or partial assessments
(weight and blood pressure or weight only) for Cohort 1 at 1-year and Cohort 2 at 1-year
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were totaled and the overall assessment completion percentages was calculated based on
the total number of participants enrolled in the study for Cohort 1 (n = 67) and Cohort 2
(n = 92).
A comparison was conducted to test the statistical significance of the average
weight loss for cohort 1 pre-COVID and for cohort 2 during COVID by diet group using
t- tests. DD model was utilized to estimate differences in average weight loss of study
participants pre COVID-19 and during COVID-19 while adjusting for patient and
intervention characteristics (age, sex, education, employment, class attendance and
physical activity). All analyses were completed using SAS version 9.4. This study was
approved by the University of South Carolina Institutional Review Board. Results
Across the two cohorts, the majority of NEW Soul participants completed
assessments both pre COVID-19 and during COVID-19. Full or partial assessment
completion at 1-year prior to COVID-19 and during COVID-19 fell within the 80th
percentile (Table 5.7).
Table 5.7- Assessment Completion at 1-year Pre COVID-19 and During COVID-19

Cohort 1: 1-year
assessments (not
impacted by COVID)
Cohort 2: 1-year
assessments (impacted by
COVID)

Full/Partial Assessment
Completion
59/67

Full/Partial Assessment
Completion Percentage
88%

74/92

80%

Cohort 1 (pre-COVID) experienced an average weight loss of 10.2 pounds
between baseline and 12 months. Cohort 2 (during COVID) experienced an average
weight loss of 3.7 pounds between baseline and 12 months (Table.5.8).
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Table 5.8- Comparison of Weight Loss by Cohort for each Diet Group
Diet
Weight
C1
C2(n=32)
Group (lbs)
(n=21)

Omni

Normality
assumption
check

Equality of Variances t Tests
Tests check

satisfied
based on QQ plot

F value=1.25,
numerator
DF/denominator
DF=20/31, p=0.5619,
pooled t test
F value=1.24,
numerator
DF/denominator
DF=20/31, p=0.5723,
pooled t test
F value=2.56,
numerator
DF/denominator
DF=20/31, p=0.0182,
satterthwaite t test

t
value=0.98,
DF=51,
p=0.3338

F value=1.56,
numerator
DF/denominator
DF=18/32, p=0.2637,
pooled t test

t value=1.31,
DF=50,
p=0.1953

mean ±
sd
216.77 ±
47.27

(Min,
Max)
( 129.41,
302.8 )

Weight at
month 12

220.83 ± ( 139.11 ,
53.59
376.77 )

212.78 ±
48.06

( 124.12,
318.79 )

satisfied
based on QQ plot

weight
change in
month 12,
compared
to
baseline

-9.51 ±
16.24

( -36.82,
15.98 )

satisfied
based on QQ plot

( 165.57,
304.24 )

satisfied
based on QQ plot
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Weight at
baseline

mean ±
(Min, Max)
sd
230.35 ± ( 140.21 ,
52.88
357.81 )

Vegan Weight at
baseline

( -41.78 , 19.84 -3.99 ±
)
10.15

C1
(n=19)
214.73 ± ( 150.8 ,
45.73
295.75 )

t
value=0.57,
DF=51,
p=0.571
t value=1.39,
DF=30.28,
p=0.1746

C2(n=33)
229.9 ±
36.58

Weight at
month 12

203.73 ± ( 148.59 ,
43.89
269.51 )

226.42 ±
38.74

( 161.6 ,
298.95 )

satisfied
based on QQ plot

weight
change in
month 12,
compared
to
baseline

-11 ±
10.33

-3.47 ±
13.5

( -44.75 ,
28.66 )

satisfied
based on QQ plot

( -34.72 , 1.87
)

F value=1.28,
numerator
DF/denominator
DF=18/32, p=0.5228,
pooled t test
F value=1.71,
numerator
DF/denominator
DF=32/18, p=0.232,
pooled t test

t value=1.94,
DF=50,
p=0.0583
t value=2.1,
DF=50,
p=0.0408
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Covariates in the models that were statistically significant with weight loss were:
time, sex and the interaction of time and cohort.. Males were found to be on average, 32
pounds. heavier than female participants. The coefficients of the interaction variable in
Table 5.9 indicates that the difference-in-differences of weight loss pre-COVID and
during COVID between cohorts was 6.5 pounds. The difference-in-differences in weight
loss pre-COVID and during COVID by diet group revealed a statistically significant
change in weight loss at 12 months compared to baseline between cohorts 1 and 2 for the
vegan diet group (p=0.0408). Pre-COVID (C1), the vegan diet group lost an average of 11
pounds. During COVID (C2), the vegan diet group lost an average of 3.47 pounds. (Table
5.10)
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Table 5.9- DD Model Findings
Effect
Intercept
t
Cohort
t*Cohort

Diet Group
Age
Sex

levels
At month 12
At baseline
1
2
At month
12*Cohort1
At month
12*Cohort2
At
baseline*Cohort1
At
baseline*Cohort2
Vegan
Omni

Male
Female
Physical activity High
Low
Moderate
Class_Attendance
High school or
Education
equivalent, Some
college
College
Advanced degree
Employment
Unemployed
Employed

Std
DF
Error
210.14 29.7624 94
-3.7258 1.5576 103
0
.
.
4.0314 9.4131 103
0
.
.
Estimate

t Value Pr > |t|
7.06
-2.39
.
0.43
.

<.0001
0.0186
.
0.6693
.

-6.4926 2.5236 103 -2.57

0.0115

0

.

.

.

.

0

.

.

.

.

0

.

.

.

.

0.22
.
0.82
2.48
.
-1.62
-1.26
.
-0.51

0.8259
.
0.4135
0.0146
.
0.1087
0.2088
.
0.6142

1.9107 8.6658 103
0
.
.
0.4183 0.5095 103
32.1905 12.9644 103
0
.
.
-19.5445 12.0776 103
-12.77 10.0976 103
0
.
.
-0.1628 0.3219 103
3.4694

11.9441 103 0.29

0.772

19.8053
0
-2.2655
0

10.2925 103
.
.
13.7253 103
.
.

0.0571
.
0.8692
.
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1.92
.
-0.17
.

Table 5.10- DD COVID-19 Effect on Weight loss by Cohort and Diet Group
Normality
Equality of
Diet
Weight C 1
C2
assumption
Variances
Group (lbs)
(n=21)
(n=32)
check
Tests check
mean ±
sd

Omni

(Min, mean ±
Max) sd

(Min,
Max)

(
Weight
140.2
230.35 ±
216.77
at
1,
52.88
± 47.27
baseline
357.8
1)

(
129.41
, 302.8
)

satisfied
based on Q-Q
plot

(
139.1
220.83 ±
212.78
1,
53.59
± 48.06
376.7
7)

(
124.12
,
318.79
)

satisfied
based on Q-Q
plot

(36.82 ,
15.98 )

satisfied
based on Q-Q
plot

Weight
at
month
12

weight
change
in
-9.51 ±
month
16.24
12,
comp.
to
baseline

(41.78
-3.99 ±
,
10.15
19.84
)

t Tests
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F
value=1.25,
numerator
DF/denomin
ator
DF=20/31,
p=0.5619,
pooled t test
F
value=1.24,
numerator
DF/denomin
ator
DF=20/31,
p=0.5723,
pooled t test
F
value=2.56,
numerator
DF/denomin
ator
DF=20/31,
p=0.0182,
satterthwaite
t test

t value=0.98,
DF=51,
p=0.3338

t value=0.57,
DF=51, p=0.571

t value=-1.39,
DF=30.28,
p=0.1746

C1
(n=19)

Vegan

C2
(n=33)

(
Weight
150.8
214.73 ±
229.9 ±
at
,
45.73
36.58
baseline
295.7
5)

(
165.57
,
304.24
)

satisfied
based on Q-Q
plot

(
148.5
203.73 ±
226.42
9,
43.89
± 38.74
269.5
1)

( 161.6
,
298.95
)

satisfied
based on Q-Q
plot

(44.75 ,
28.66 )

satisfied
based on Q-Q
plot

Weight
at
month
12

weight
change
in
-11 ±
month
10.33
12,
comp to
baseline

(34.72 -3.47 ±
, 1.87 13.5
)
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F
value=1.56,
numerator
DF/denomin
ator
DF=18/32,
p=0.2637,
pooled t test
F
value=1.28,
numerator
DF/denomin
ator
DF=18/32,
p=0.5228,
pooled t test
F
value=1.71,
numerator
DF/denomin
ator
DF=32/18,
p=0.232,
pooled t test

t value=-1.31,
DF=50,
p=0.1953

t value=-1.94,
DF=50,
p=0.0583

t value=-2.1,
DF=50,
p=0.0408

Discussion
As measures are being taken to vaccinate the population against COVID-19, the
literature revealed that quarantine and isolation has disproportionately affected
individuals in the US with obesity and their ability to manage their weight and health
behaviors despite COVID-19 illness status.148 When asked, patients in health care
settings and public survey respondents consistently reported: spending more time at
home; hardships achieving/maintaining weight loss goals; decreased physical activity;
increased stress eating; decreased dietary restraint; and an increase in anxiety and
depression.148,149,150 A systematic review of the literature that included 36 studies
identified similar trends at the global level.153 However, a critical gap in knowledge about
the impact of COVID-19 on African Americans were largely underrepresented in these
studies. In this study, we will provide insights on whether the pandemic had an impact on
weight loss of AAs enrolled in the NEW Soul Study. Additionally, we will help inform
participant levels of comfort to voluntarily complete clinical assessments (where study
measures such as weight and blood pressure were collected) based on procedures
implemented to mitigate the risk and spread of illness during assessment visits.
Across the two cohorts, the majority of NEW Soul participants completed
assessments both pre COVID-19 and during COVID-19. Assessment participation
percentages at 1-year prior to COVID-19 and during COVID-19 both fell within the 80th
percentile, which may be associated with several factors that contributed to high levels of
comfort. Participants received detailed communications regarding the protocol to conduct
assessments in the safest way possible. These communications were delivered via phone,
text message and email. Despite participants having the option to not complete
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assessments, most completed either full or partial in-person assessments at the
University.
Additionally, this study revealed that pre-COVID weight loss of participants not
impacted by COVID (cohort 1) was greater at 12 months, as compared to weight loss of
participants impacted by COVID (cohort 2) at 12 months. Furthermore, this study
revealed that participants in the vegan diet group had a harder time achieving weight loss
during the COVID-19 pandemic. These findings were consistent with reported weight
gain during the COVID-19 pandemic in individuals (mostly with overweight and obesity)
across 38 studies who reported eating and snacking more, less consumption of
vegetables, fruit and legumes, and more consumption of meat, dairy, fast-food and
alcohol.153,164,165 Furthermore, household size changes, employment changes, COVID-19
diagnosis or death of individuals or their family members, and lifestyle behaviors were
reported contributors of weight gain.165
This study is not without limitations due to assumptions related to the quasiexperimental design method. This DD analysis assumes that the composition of Cohort 1
and Cohort 2 are stable during baseline and 12 months. In a DD study design it is also
assumed that: there are no spillover effects that unrelated events had on both cohorts; the
amount of intervention provided is not determined by weight loss; and both cohorts have
parallel trends in weight loss outcomes if no intervention was provided so that the
difference between the data from the cohorts would have a consistent difference over
time.135
Threats to the validity of the study include: attrition and measurement error.
Attrition is a threat to the validity of this study, because not all participants participated in
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the 12 month assessment where weight was collected. Measurement error may have also
resulted during the collection of weight and/or during the entry of that data.
Significant measures were taken by the NEW Soul Staff to assure the reliability
and validity of the data. These measures included: frequent communication with
participants to maximize participation in assessments to collect weight; and collecting
two weight measurements that were recorded and triple checked upon entering the data.
Despite these challenges, there are some strengths of this study. The DD method
is flexible and will show a casual effect from experimental data when the basic
assumptions are met. The DD method is a controlled pre and post analysis that focuses on
changes of the cohorts at different time points and changes due to factors outside of the
vegan and omni interventions of the NEW Soul Study.
Conclusion
While this study presents a DD estimation of the impact of COVID-19 on weight
loss for AAs presenting with heart disease risk factors, more work is needed to fully
understand this association. This study demonstrates that participants impacted by
COVID experienced less weight loss than participants who were not impacted by
COVID. This signifies a need to develop lifestyle interventions that include culturallytailored curriculum to help vulnerable populations with overweight or obesity achieve
weight loss during times of extended crisis.
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